[
    {
        "category": "company",
        "datetime": 1743528180,
        "headline": "AstraZeneca PLC ADR falls Tuesday, underperforms market",
        "id": 133690170,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca PLC ADR falls Tuesday, underperforms market",
        "url": "https://finnhub.io/api/news?id=8e93777faac2b0e2b0ecdb91b466f754f04eb968c11cdbc081cefb0c39ae0f78"
    },
    {
        "category": "company",
        "datetime": 1743518040,
        "headline": "Impax International Sustainable Economy Fund Q4 2024 Commentary",
        "id": 133655381,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1393825226/image_1393825226.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "During the fourth quarter of 2024, Impax International Sustainable Economy Fund underperformed the MSCI EAFE benchmark. Read more here.",
        "url": "https://finnhub.io/api/news?id=90cf55d081c36dcedac61b4bebee0440b2a33a47a9e41f79050b0b3ec6df1b17"
    },
    {
        "category": "company",
        "datetime": 1743514260,
        "headline": "AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication",
        "id": 133646268,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.",
        "url": "https://finnhub.io/api/news?id=c13583783b545337be99d92a10446325c210884e79746252cdcf2264e0fd8b6c"
    },
    {
        "category": "company",
        "datetime": 1743507364,
        "headline": "AstraZeneca\u2019s AZD0780 cuts LDL-C by 50% in Phase IIb trial",
        "id": 133646270,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The company reported results from the Phase IIb PURSUIT trial at ACC 2025.",
        "url": "https://finnhub.io/api/news?id=237d9ee6675f493046ed95847d070d9661e4183baba2d0c627fb77850ce2b23c"
    },
    {
        "category": "company",
        "datetime": 1743506836,
        "headline": "Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins",
        "id": 133645184,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The latest investor updates on stocks that are trending on Tuesday.",
        "url": "https://finnhub.io/api/news?id=37c7aacd6edd990b639e66860f7b4b24fc51b6b6fb7f791287597fcb15bed199"
    },
    {
        "category": "company",
        "datetime": 1743496044,
        "headline": "FDA approves AstraZeneca\u2019s Imfinzi combo for bladder cancer",
        "id": 133633314,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The decision follows a priority review and is based on data from the Phase III NIAGARA trial.",
        "url": "https://finnhub.io/api/news?id=1089029d385569f730688398b28107b34de8e05808b3f353d512a9393606e712"
    },
    {
        "category": "company",
        "datetime": 1743455391,
        "headline": "SPEU:\u00a0 A Solid Choice For Exposure To The Hot European Market",
        "id": 133630541,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159044105/image_2159044105.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "European equities, via the SPEU ETF, outshine U.S. equities this year with better value, higher yields, and diversified sector exposure. See more here.",
        "url": "https://finnhub.io/api/news?id=7c50b8494899ed7e9990f4ffa04450f60d7e41184dd1f2b6d071c3c56c581985"
    },
    {
        "category": "company",
        "datetime": 1743446174,
        "headline": "FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients",
        "id": 133633315,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) for adult patients with muscle-invasive bladder cancer (MIBC). The FDA approval was based on results from the NIAGARA Phase 3 trial. In a planned interim analysis, the Imfinzi-based perioperative regimen demonstr",
        "url": "https://finnhub.io/api/news?id=17d87caefeb0aa6f519b022767532511b75f4a8ebeacc944bc86b29e59d61e45"
    },
    {
        "category": "company",
        "datetime": 1743438127,
        "headline": "Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?",
        "id": 133627819,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca said Monday its experimental pill lowered \"bad\" LDL cholesterol by 51%. But AstraZeneca stock fell in line with pharma stocks.",
        "url": "https://finnhub.io/api/news?id=28a26f90e943889317642c2b0c0676b9cd4e9c665cbe123f60b6ac1ce77b0eab"
    },
    {
        "category": "company",
        "datetime": 1743436800,
        "headline": "\u200b\u200bAZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial",
        "id": 133628227,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "WILMINGTON, Del., March 31, 2025--Positive results from the PURSUIT Phase IIb trial for AstraZeneca\u2019s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo.1,2 AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care-lipid lowering therapies such as statins.1,2",
        "url": "https://finnhub.io/api/news?id=985893d381df10d6535a0a9f0b9f56f6d148e7839df9df84e6b276e847090588"
    },
    {
        "category": "company",
        "datetime": 1743428400,
        "headline": "JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer",
        "id": 133628228,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of care in certain NSCLC patients.",
        "url": "https://finnhub.io/api/news?id=935d73dd621b9b7a96a24629791b3d25a8d7b6d7c731931f08b3e3d56f72b060"
    },
    {
        "category": "company",
        "datetime": 1743423518,
        "headline": "Stocks to Watch Monday: Nvidia, Tesla, Moderna, Stellantis",
        "id": 133625807,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "\u2198\ufe0f Nvidia (NVDA): Shares of the artificial-intelligence bellwether fell more than 4% in premarket trading. CoreWeave (CRWV), the Nvidia-backed AI startup that went public last week, also fell before the bell.",
        "url": "https://finnhub.io/api/news?id=e5da1815fa5cb2c39bcea29094d445cd8ca554f224271a188becc1c7791db5d5"
    },
    {
        "category": "company",
        "datetime": 1743418800,
        "headline": "IMFINZI\u00ae (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer",
        "id": 133625814,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "WILMINGTON, Del., March 31, 2025--AstraZeneca\u2019s IMFINZI\u00ae (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).",
        "url": "https://finnhub.io/api/news?id=7cdee6cc22dfbdb7cf0ae5d9f865a2220d7c2064266b10433a857c1f7c7de21b"
    },
    {
        "category": "company",
        "datetime": 1743414300,
        "headline": "PGIM Jennison Value Fund Q4 2024 Commentary",
        "id": 133626380,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163730037/image_2163730037.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The PGIM Jennison Value Fund advanced and outperformed the Russell 1000 Value Index during Q4 2024. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=278d9829a07c13d3f4771e964b3454bce1732917eeb089344861f85d222c734f"
    },
    {
        "category": "company",
        "datetime": 1743406680,
        "headline": "AstraZeneca's Muscle-Invasive Bladder Cancer Treatment Gets FDA Approval",
        "id": 133690171,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca's Muscle-Invasive Bladder Cancer Treatment Gets FDA Approval",
        "url": "https://finnhub.io/api/news?id=3ea860c3f3799c395734e77c1b62aed9380f293905796fee40b80ab2079db3b2"
    },
    {
        "category": "company",
        "datetime": 1743390900,
        "headline": "John Hancock International Growth Fund Q4 2024 Commentary",
        "id": 133623666,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/875074116/image_875074116.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The John Hancock International Growth Fund outperformed the MSCI All Country World ex-USA Growth Index for Q4 2024. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=8455d7653be75aca4bf3aeabfd4713619fc3ee6f21de4a8ad5a9a2b15fcca3f7"
    },
    {
        "category": "company",
        "datetime": 1743323220,
        "headline": "Hartford International Growth Fund Q4 2024 Commentary",
        "id": 133610492,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912015114/image_912015114.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Hartford International Growth Fund (I Share) outperformed the MSCI ACWI ex USA Growth Net Index during the quarter. Read more here.",
        "url": "https://finnhub.io/api/news?id=0d920568a09a8d40b6a5733102b689f9df46b5a00e675197d3b3f705d3228519"
    },
    {
        "category": "company",
        "datetime": 1743310800,
        "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
        "id": 133598030,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453972690/image_1453972690.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
        "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87"
    },
    {
        "category": "company",
        "datetime": 1743206760,
        "headline": "PGIM Jennison Focused Value Fund Q4 2024 Commentary",
        "id": 133526446,
        "image": "",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=366e6cf744a8cddb0af116bc4d3af12181226e5a34a179a0f5babf04c1f1f565"
    },
    {
        "category": "company",
        "datetime": 1743206100,
        "headline": "PGIM Jennison Blend Fund Q4 2024 Commentary",
        "id": 133526379,
        "image": "",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=e8c81c0527072f874f76c8eb4c6106afdf4f82c6ccb52e4adcc553cb3fbe9e17"
    },
    {
        "category": "company",
        "datetime": 1743197023,
        "headline": "Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds?",
        "id": 133527739,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other best ADR stocks. American Depositary Receipts (ADR) are US-listed securities that represent shares in foreign companies, allowing American investors [\u2026]",
        "url": "https://finnhub.io/api/news?id=9797dc83b5bca312cf235879fb9bc47c60f53022440d70734bf645a4b1f1ef14"
    },
    {
        "category": "company",
        "datetime": 1743182520,
        "headline": "AstraZeneca PLC ADR outperforms competitors on strong trading day",
        "id": 133690172,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca PLC ADR outperforms competitors on strong trading day",
        "url": "https://finnhub.io/api/news?id=b59dc4a0587b481b853099ab088ae19db2a59b6dcfa2c621c631e217550fda51"
    },
    {
        "category": "company",
        "datetime": 1743082210,
        "headline": "Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet",
        "id": 133482009,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
        "url": "https://finnhub.io/api/news?id=55f10d07e58d1ebc01eac7d483a5afa6708ecaf2fcb0ee71193d59e81f4b721c"
    },
    {
        "category": "company",
        "datetime": 1743060600,
        "headline": "Franklin Biotechnology Discovery Fund Q4 2024 Commentary",
        "id": 133467152,
        "image": "",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=743b5137aca60badcb2ace1e5601b3a1d46e916bce67c484c60523c28bfb157b"
    },
    {
        "category": "company",
        "datetime": 1743060464,
        "headline": "How AZ and Amgen\u2019s Tezspire respiratory data ups the \u2018level of ambition\u2019 in immunology",
        "id": 133468095,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.",
        "url": "https://finnhub.io/api/news?id=001537c9d63008da192689c14cdcb2294b824b9e6b60e58388eb79d4ee37fa02"
    },
    {
        "category": "company",
        "datetime": 1743030320,
        "headline": "AstraZeneca says new results reinforce Tagrisso as backbone therapy",
        "id": 133462768,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca\u2019s (AZN) TAGRISSO, as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include: LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy; SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with h",
        "url": "https://finnhub.io/api/news?id=210dd4aef48ff46fcf6c31b8ed3842899d231cd997ac4bb6e1c05efd4bd0a4f1"
    },
    {
        "category": "company",
        "datetime": 1743027314,
        "headline": "Astrazeneca (AZN) Stock Moves -0.45%: What You Should Know",
        "id": 133462770,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "In the most recent trading session, Astrazeneca (AZN) closed at $72.72, indicating a -0.45% shift from the previous trading day.",
        "url": "https://finnhub.io/api/news?id=38da968a665e8db17923827c3b202bf904687deb28bfb4221cf9f9f0565ebfac"
    },
    {
        "category": "company",
        "datetime": 1742943720,
        "headline": "New study results reinforce TAGRISSO\u00ae (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings",
        "id": 133448993,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "WILMINGTON, Del., March 25, 2025--New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca\u2019s TAGRISSO\u00ae (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Highlights include:",
        "url": "https://finnhub.io/api/news?id=3bbc931085145102a54cfd30c4b00b5a55d730379b5ab545a000047d96d968f1"
    },
    {
        "category": "company",
        "datetime": 1742888820,
        "headline": "Fidelity Freedom Income Fund Q4 2024 Review",
        "id": 133371562,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2151803518/image_2151803518.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The fourth quarter of 2024 was volatile for most asset classes against a backdrop of the U.S. election, surging dollar strength, sticky inflation and rising interest rates in some markets.",
        "url": "https://finnhub.io/api/news?id=84e737ef84266945491ec7c1c5932c43b03cd87a3794cc019f128dd16db841cb"
    },
    {
        "category": "company",
        "datetime": 1742836920,
        "headline": "AstraZeneca PLC ADR underperforms Monday when compared to competitors",
        "id": 133420503,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca PLC ADR underperforms Monday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=bf52920cbe1688a4fa91fecc724557725f40822b3a95dd51f13a8a92eeab4437"
    },
    {
        "category": "company",
        "datetime": 1742836374,
        "headline": "Assemblin to upgrade AstraZeneca\u2019s G\u00e4rtuna plant in Sweden",
        "id": 133350208,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The upgrade focuses on enhancing the cooling capacity at the plant and supplying supplementary equipment installation.",
        "url": "https://finnhub.io/api/news?id=d0b21071eb936c4863f1c1856309394691ab96e2dcddcd339e1852a57c2f46db"
    },
    {
        "category": "company",
        "datetime": 1742824592,
        "headline": "Argenx: The Magic May Be Already Priced In",
        "id": 133352325,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2184219690/image_2184219690.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ARGX stock here.",
        "url": "https://finnhub.io/api/news?id=0d2cee3752538f8b5993d1f1bf07d4f8c09a0f5d431d22d4713bb2b764bffc41"
    },
    {
        "category": "company",
        "datetime": 1742821208,
        "headline": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
        "id": 133350209,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
        "url": "https://finnhub.io/api/news?id=131d33ec649b3eacee4a76efeff9cdb50b18f695c199a1d1023c0e630ecf9e02"
    },
    {
        "category": "company",
        "datetime": 1742808043,
        "headline": "AstraZeneca to invest $2.5bn in R&D centre in China",
        "id": 133338391,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The new centre will focus on early-stage research and clinical development, supported by data science and AI labs.",
        "url": "https://finnhub.io/api/news?id=864c8f5bdfc26c3ce0861609adaac14a062c1d4bef322edffec3e9c8a441cf28"
    },
    {
        "category": "company",
        "datetime": 1742770800,
        "headline": "Harbour BioMed Shares Soar on News of AstraZeneca Collaboration",
        "id": 133420505,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "Harbour BioMed Shares Soar on News of AstraZeneca Collaboration",
        "url": "https://finnhub.io/api/news?id=bb9438427e733ddb3f3b591d04b37fca7c22d3e98823ada13cd9a2534a2f756c"
    },
    {
        "category": "company",
        "datetime": 1742724300,
        "headline": "Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead",
        "id": 133338392,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca (NASDAQ: AZN), a U.K.-based pharmaceutical giant, is one of them; its stock is up by an impressive 16% since January.  AstraZeneca's shares fell off a cliff late last year when it announced the arrest of some of its executives in China, including Leon Wang, the drugmaker's president in the country.  Last year, its revenue jumped by 18% year over year to $54.1 billion, an excellent performance for a pharmaceutical giant.",
        "url": "https://finnhub.io/api/news?id=b2eaa0e281ba041b2eac53e0a043b7679064905aaf67d81232ff1b1e4ce29a91"
    },
    {
        "category": "company",
        "datetime": 1742586569,
        "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
        "id": 133338393,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.6% and the Hea",
        "url": "https://finnhub.io/api/news?id=93647cf10bde5db7acebbdb4a31aa00d03d2eafbf6875206265e3dbf960ac534"
    },
    {
        "category": "company",
        "datetime": 1742577840,
        "headline": "AstraZeneca PLC ADR falls Friday, underperforms market",
        "id": 133420507,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca PLC ADR falls Friday, underperforms market",
        "url": "https://finnhub.io/api/news?id=67d9f7ff93c87dceaf0ad8c0ed8be225b4aa9820fa7c4ad69418dd3da4a6da3d"
    },
    {
        "category": "company",
        "datetime": 1742574360,
        "headline": "Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals",
        "id": 133325250,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Pfizer sells 7.3% remaining stake in Haleon. FDA approves the expanded use of JNJ and NVS drugs.",
        "url": "https://finnhub.io/api/news?id=fb509bcc99311a52bf6d0e75ff756996ad6a6fc3dffd19d1e285b17504cf5f01"
    },
    {
        "category": "company",
        "datetime": 1742571031,
        "headline": "Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?",
        "id": 133338395,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=997696efe4374f37ba24f77369b0d6eddffa1073847268896b607f758e45c879"
    },
    {
        "category": "company",
        "datetime": 1742567968,
        "headline": "AstraZeneca to invest \u00a32bn in Beijing amid China investigation",
        "id": 133338396,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca has unveiled plans to invest \u00a32bn in Beijing months after Chinese authorities detained the company\u2019s local boss over alleged illegal activity.",
        "url": "https://finnhub.io/api/news?id=c73a8a610694ca9742e347dd81255e6c68cb3832440d6b2aaabfe6e920370f85"
    },
    {
        "category": "company",
        "datetime": 1742566782,
        "headline": "Micron, Johnson & Johnson, AstraZeneca: Top Stocks",
        "id": 133325538,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Morning Brief host Brad Smith tracks several of this morning's trending stocks and market stories, including Micron Technology's (MU) guidance overshadowing its fiscal second quarter results, Johnson & Johnson's (JNJ) plans to invest in US manufacturing, and AstraZeneca's (AZN) own investment into a Beijing facility. To watch more expert insights and analysis on the latest market action, check out more Morning Brief\u00a0here.",
        "url": "https://finnhub.io/api/news?id=e9a635b2273defbfcc7166ea7c38ccc0c4b643eb2cbbb9a238c4efd90073d051"
    },
    {
        "category": "company",
        "datetime": 1742563500,
        "headline": "AstraZeneca to Invest $2.5 Billion in China Amid Probes",
        "id": 133338398,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies, at a time when Chinese authorities are probing it.",
        "url": "https://finnhub.io/api/news?id=8e9c0324134ef9fe78b36d1abe0e0832c0cdf29c4c529c3de0c2a259c95bff87"
    },
    {
        "category": "company",
        "datetime": 1742559300,
        "headline": "AstraZeneca deepens China investment; Editas loses CFO to Dyne",
        "id": 133325254,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The pharma is spending $2.5 billion on an\u00a0R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.",
        "url": "https://finnhub.io/api/news?id=f486532ada742e61b2d5f300defe46053b2af5ac9e4a91ecf301108f6377e8ae"
    },
    {
        "category": "company",
        "datetime": 1742557733,
        "headline": "AstraZeneca Invests $2.5 Billion in Beijing Hub Amid Probe",
        "id": 133338400,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "(Bloomberg) -- AstraZeneca Plc will invest $2.5 billion in a new research center in Beijing, in a major show of commitment to China just months after the company\u2019s top executive there was detained by authorities. Most Read from BloombergNew York Subway Ditches MetroCard After 32 Years for Tap-And-GoLA Faces $1 Billion Budget Hole, Warns of Thousands of LayoffsDespite Cost-Cutting Moves, Trump Plans to Remake DC in His StyleAmtrak CEO Departs Amid Threats of a Transit Funding PullbackChicago Tran",
        "url": "https://finnhub.io/api/news?id=63d9e425d1a39b753cbad3488e9d9b3ef57751b3dc565ff40d9aaca37ba6c0fb"
    },
    {
        "category": "company",
        "datetime": 1742556633,
        "headline": "AstraZeneca to invest $2.5bn in China after scandal",
        "id": 133338401,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca is investing $2.5bn in research and development and manufacturing in Beijing, as the drugmaker tries to move on after a scandal that...",
        "url": "https://finnhub.io/api/news?id=b12854ab6028d3d83b129e7fa7352ab18bd14f66fb454a272abe75be0ca489e6"
    },
    {
        "category": "company",
        "datetime": 1742555019,
        "headline": "AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals",
        "id": 133338402,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.  Chief Executive Pascal Soriot was in Beijing and met with the city's mayor to reveal the investment, along with two licensing deals with Chinese companies, and a joint venture with a third Chinese firm on vaccines, saying they all showed the company's commitment to the world's No. 2 economy.  \"This $2.5 billion investment reflects our belief in the world-class life sciences ecosystem in Beijing, the extensive opportunities that exist for collaboration and access to talent, and our continued commitment to China,\" Soriot said in a statement.",
        "url": "https://finnhub.io/api/news?id=d076fbbdeb727922786a8942b6fc3b616124e3eb05888f2717f425cec91018bf"
    },
    {
        "category": "company",
        "datetime": 1742541707,
        "headline": "Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy",
        "id": 133297533,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1444529209/image_1444529209.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.",
        "url": "https://finnhub.io/api/news?id=2012cfbaa433b0233c82b4e2650cde3928bdf1857ae5c68c2d115d433190debb"
    },
    {
        "category": "company",
        "datetime": 1742475491,
        "headline": "Here\u2019s Why Parnassus Growth Equity Fund Decided to Sell AstraZeneca PLC (AZN)",
        "id": 133338403,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Parnassus Investments, an investment management company, released the \u201cParnassus Growth Equity Fund\u201d fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, the Fund (Investor Shares) returned 4.85% (net of fees) underperforming the Russell 1000 Growth Index\u2019s 7.07% gain. For the year, the fund returned 26.85% compared [\u2026]",
        "url": "https://finnhub.io/api/news?id=bcd86e940b67d75dd9d65ed8784af43b04de6a03ee806bd992911f5254b35fd7"
    },
    {
        "category": "company",
        "datetime": 1742422517,
        "headline": "Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know",
        "id": 133338404,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The latest trading day saw Astrazeneca (AZN) settling at $76.32, representing a -0.97% change from its previous close.",
        "url": "https://finnhub.io/api/news?id=2f590613ce5921dc2f5486dc51ec2190cb65bffaefa77ccc118242369441aba8"
    },
    {
        "category": "company",
        "datetime": 1742419260,
        "headline": "BlackRock Global Dividend Fund Q4 2024 Commentary",
        "id": 133263378,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/96502248/image_96502248.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "BlackRock Global Dividend Fund posted returns of -4.66% (Institutional shares) and -4.64% (Investor A shares, without sales charge) for the fourth quarter of 2024.",
        "url": "https://finnhub.io/api/news?id=fe11fccefad920397ae12f7f4e4eda84c9f64cb98b126478d861edcec76868c3"
    },
    {
        "category": "company",
        "datetime": 1742393935,
        "headline": "AstraZeneca (AZN): Among the Best Diabetes Stocks to Buy According to Billionaires",
        "id": 133338405,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best diabetes stocks to buy according to billionaires. The Growing Market and Innovation in Continuous Glucose Monitoring (CGM) Technology The WHO estimates [\u2026]",
        "url": "https://finnhub.io/api/news?id=e901d83ab87a4d4823217811d0b9f5357a71f9713a151ab61de1bae623f6778d"
    },
    {
        "category": "company",
        "datetime": 1742364467,
        "headline": "3 UK Stocks Estimated To Be Trading At Discounts Of Up To 48.5%",
        "id": 133331180,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index slipping due to weak trade data from China, highlighting concerns over global economic recovery. In this environment, identifying undervalued stocks can be a strategic approach for investors seeking potential opportunities amidst broader market fluctuations.",
        "url": "https://finnhub.io/api/news?id=e1fc9b7cb9dba76ad5a337eb5acf3f34536cf8c3417853296c3c01745686d13a"
    },
    {
        "category": "company",
        "datetime": 1742302074,
        "headline": "Is AstraZeneca (AZN) the Best European Stock to Buy According to Billionaires?",
        "id": 133338407,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently published a list of 10 Best European Stocks to Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best European stocks to buy according to billionaires. On March 12, European markets opened on a high note, surging after the European [\u2026]",
        "url": "https://finnhub.io/api/news?id=85e72fdc194052a5fe59c78c01ee8b03fb422e1ea70fea3aaaa5314f3981abd0"
    },
    {
        "category": "company",
        "datetime": 1742300328,
        "headline": "AstraZeneca\u2019s $1bn hypoparathyroidism drug achieves success at Phase III",
        "id": 133338408,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca acquired eneboparatide as part of a buyout of Amolyt Pharma in July 2024.",
        "url": "https://finnhub.io/api/news?id=7a01ead874f76c6f5a6b2eedbf072d8270446eaeb76507de9ffc505e1a3b7881"
    },
    {
        "category": "company",
        "datetime": 1742299500,
        "headline": "Stoke CEO exits; Medicare drug price talks advance",
        "id": 133327551,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Ed Kaye, Stoke\u2019s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers targeted for second round of Medicare price talks agreed to participate.",
        "url": "https://finnhub.io/api/news?id=03c6e063f8b9ee00754132703c0de5a55b1975d30a0aafa33d0fd8eeebb1077d"
    },
    {
        "category": "company",
        "datetime": 1742290323,
        "headline": "AstraZeneca and Alteogen agree on ALT-B4 platform tech",
        "id": 133338410,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca will obtain worldwide rights for using ALT-B4.",
        "url": "https://finnhub.io/api/news?id=0d120fdae4e2a8ad859b810d2ea40681d64f4c5b6e180aad39e6e94486f914d2"
    },
    {
        "category": "company",
        "datetime": 1742284800,
        "headline": "Fidelity Freedom 2065 Fund Q4 2024 Review",
        "id": 133216408,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1474796041/image_1474796041.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The fourth quarter of 2024 was volatile for most asset classes against a backdrop of the U.S. election, surging dollar strength, sticky inflation and rising interest rates in some markets.",
        "url": "https://finnhub.io/api/news?id=c00d83ce9e039689b72f61aeb66497375008ce99fce16f186a448f499d3f4ac1"
    },
    {
        "category": "company",
        "datetime": 1742277900,
        "headline": "Fidelity Freedom 2060 Fund Q4 2024 Review",
        "id": 133215633,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688767071/image_1688767071.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The fourth quarter of 2024 was volatile for most asset classes against a backdrop of the U.S. election, surging dollar strength, sticky inflation and rising interest rates in some markets.",
        "url": "https://finnhub.io/api/news?id=02ad0e9cc8f7757dc14d5d8c716c946a1605b03683b662149451832194c9ddb1"
    },
    {
        "category": "company",
        "datetime": 1742255700,
        "headline": "Fidelity Freedom 2055 Fund Q4 2024 Review",
        "id": 133211330,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1990350865/image_1990350865.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Federal Reserve continued its easing cycle in Q4, yet higher-than-expected inflation in December led the Fed to signal a slowing of the pace of rate cuts.",
        "url": "https://finnhub.io/api/news?id=b74345d4b44dad6e4a183852b978d83bc731b0bbf0cc98061392d3f98ddca9a9"
    },
    {
        "category": "company",
        "datetime": 1742251860,
        "headline": "Fidelity Freedom 2050 Fund Q4 2024 Review",
        "id": 133211056,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1020260704/image_1020260704.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Federal Reserve continued its easing cycle in Q4, yet higher-than-expected inflation in December led the Fed to signal a slowing of the pace of rate cuts.",
        "url": "https://finnhub.io/api/news?id=ce054c4148b03ee5f566d6887dac5a58a89fe4fe5e5bb05cd312afc1e93990b1"
    },
    {
        "category": "company",
        "datetime": 1742248920,
        "headline": "Fidelity Freedom 2045 Fund Q4 2024 Review",
        "id": 133210919,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2147628204/image_2147628204.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The fourth quarter of 2024 was volatile for most asset classes against a backdrop of the U.S. election, surging dollar strength, sticky inflation and rising interest rates in some markets.",
        "url": "https://finnhub.io/api/news?id=66815bed75c091f881792ffdb2fe28d84c8deaf97018c076abb74c84daf0af64"
    },
    {
        "category": "company",
        "datetime": 1742247960,
        "headline": "Fidelity Freedom 2040 Fund Q4 2024 Review",
        "id": 133210854,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593688/image_1072593688.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Fidelity Freedom\u00c2\u00ae Funds are designed so that the target date referenced in the Fund name is the approximate year when investors expect to retire. Read more here.",
        "url": "https://finnhub.io/api/news?id=ab5ddffd0912ef41136b9078687f0d662609d892bafb6ffd865d94c36a0957bf"
    },
    {
        "category": "company",
        "datetime": 1742246580,
        "headline": "Fidelity Freedom 2035 Fund Q4 2024 Review",
        "id": 133210782,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1010720982/image_1010720982.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Fidelity Freedom\u00c2\u00ae Funds are designed so that the target date referenced in the Fund name is the approximate year when investors expect to retire. Read more here.",
        "url": "https://finnhub.io/api/news?id=bdabce668615772c3d0ea451fc111f80ef759d020631c366b50cba18a2a4bf84"
    },
    {
        "category": "company",
        "datetime": 1742244540,
        "headline": "Fidelity Freedom 2030 Fund Q4 2024 Review",
        "id": 133210649,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2173828929/image_2173828929.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The fourth quarter of 2024 was volatile for most asset classes against a backdrop of the U.S. election, surging dollar strength, sticky inflation and rising interest rates in some markets.",
        "url": "https://finnhub.io/api/news?id=88b2215256b6b40588b1a5a970c4da027ae7f718fd4fa91b5547b754c3e861bb"
    },
    {
        "category": "company",
        "datetime": 1742217360,
        "headline": "Fidelity Freedom 2025 Fund Q4 2024 Review",
        "id": 133208640,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2164135129/image_2164135129.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The fourth quarter of 2024 was volatile for most asset classes against a backdrop of the U.S. election, surging dollar strength, sticky inflation and rising interest rates in some markets.",
        "url": "https://finnhub.io/api/news?id=01d55286ceb516d033690f9ff7443ef4ac5e7bb2fe4e4b3ab8e201b015cae9e1"
    },
    {
        "category": "company",
        "datetime": 1742194920,
        "headline": "Fidelity Freedom 2020 Fund Q4 2024 Review",
        "id": 133206271,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1127002556/image_1127002556.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Fund's glide path and strategic asset allocation reflect our long-term views and insights on participant needs, diversification and capital markets. Read more here.",
        "url": "https://finnhub.io/api/news?id=19ca625a487f4098b54cac5d3b29889f01d75f222216ad1675e9d85d7d5f3c0c"
    },
    {
        "category": "company",
        "datetime": 1742190480,
        "headline": "Fidelity Freedom 2015 Fund Q4 2024 Review",
        "id": 133205740,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/468225502/image_468225502.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The fourth quarter of 2024 was volatile for most asset classes against a backdrop of the US election, surging dollar strength, sticky inflation and rising interest rates in some markets.",
        "url": "https://finnhub.io/api/news?id=605a4d5666da59f8b9541cfcf7dd732486bd586065318cf1cfd90015913b61f2"
    },
    {
        "category": "company",
        "datetime": 1742183220,
        "headline": "AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio",
        "id": 133260719,
        "image": "",
        "related": "AZN",
        "source": "DowJones",
        "summary": "AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio",
        "url": "https://finnhub.io/api/news?id=909a0c44b0dbf4cbdacc0471aa526a6d80a52f7ac9f08e68d808bdff34f0f726"
    },
    {
        "category": "company",
        "datetime": 1741982520,
        "headline": "AstraZeneca Stock Scores RS Rating Upgrade",
        "id": 133184262,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.",
        "url": "https://finnhub.io/api/news?id=a6bdc95763d16b3f6e8ac10b2bca3e91a0d4ed282d09b4845b98b90c25ca0d93"
    },
    {
        "category": "company",
        "datetime": 1741973951,
        "headline": "INOVIO\u2019s Covid-19 dMAb maintains in-vivo detection in 100% participants",
        "id": 133194769,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAB in their systems.",
        "url": "https://finnhub.io/api/news?id=bf2fed81da92941c2857c9a5665e83608d94995582775760dfc1d5f091aae4ea"
    },
    {
        "category": "company",
        "datetime": 1741973340,
        "headline": "AstraZeneca director says AI must be a \u201cthought partner\u201d in drug discovery",
        "id": 133194770,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca\u2019s senior director in oncology data science outlined how the company uses AI for drug discovery at a recent talk.",
        "url": "https://finnhub.io/api/news?id=d949db3252c18cecebb1de1b1b505a2490432e616c89044bdd16fcb78ad6bf8f"
    },
    {
        "category": "company",
        "datetime": 1741972860,
        "headline": "AstraZeneca PLC ADR rises Friday, still underperforms market",
        "id": 133260741,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca PLC ADR rises Friday, still underperforms market",
        "url": "https://finnhub.io/api/news?id=aa5830ef55c2ca87d205bb68385ce8267f28ad12bac24bee355590d2c6a04c67"
    },
    {
        "category": "company",
        "datetime": 1741968000,
        "headline": "AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer",
        "id": 133194771,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "WILMINGTON, Del., March 14, 2025--AstraZeneca and Erin Andrews have teamed up as part of a national public health campaign to educate and empower people to Get Body Checked Against Cancer. Erin is a passionate entrepreneur, national sports broadcaster, podcast host, hockey fan and wife \u2014 and cancer survivor.",
        "url": "https://finnhub.io/api/news?id=bdfe5b9dc3be9f20d71e3ed4f4628248f8339dff61b89fe2d686d3653425eaf3"
    },
    {
        "category": "company",
        "datetime": 1741881346,
        "headline": "AstraZeneca Stock Nears Buy Point After Long Run In Declining Market",
        "id": 133194772,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well in a declining market.  AstraZeneca stock is nearing a buy point after climbing for seven straight weeks.  The biopharmaceutical company develops drugs for cancer, immune, cardiovascular, kidney and rare diseases as well as vaccines.",
        "url": "https://finnhub.io/api/news?id=ff8b8d9bf3512dd8b9a750c52d1edf5a0bcdb032ea2e3d15fb0532fd2632574b"
    },
    {
        "category": "company",
        "datetime": 1741879827,
        "headline": "Why Is CRISPR Therapeutics (CRSP) Up 0.4% Since Last Earnings Report?",
        "id": 133194773,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=df1218e0d57efab896bc130f0427c729c2f31cddfb39f653bb793060c72312d2"
    },
    {
        "category": "company",
        "datetime": 1741817717,
        "headline": "Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know",
        "id": 133194774,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "In the latest trading session, Astrazeneca (AZN) closed at $75.57, marking a +1.79% move from the previous day.",
        "url": "https://finnhub.io/api/news?id=48d3b8af6cb54a7eb0e7891d089da5cfb7e9b6217ede33f0cf56e348d042f159"
    },
    {
        "category": "company",
        "datetime": 1741810157,
        "headline": "Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion",
        "id": 133184276,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.",
        "url": "https://finnhub.io/api/news?id=9d4ec59f6037fefdbdcd47a67f7600dc71ffa187ce9b258dd50d70a5e8a54a3c"
    },
    {
        "category": "company",
        "datetime": 1741800180,
        "headline": "AstraZeneca PLC ADR rises Wednesday, outperforms market",
        "id": 133260743,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca PLC ADR rises Wednesday, outperforms market",
        "url": "https://finnhub.io/api/news?id=8bbcfe5cb3ed86d26e71566e46a90bd0f8d3b8634c9ce55b8eee7926621d75ce"
    },
    {
        "category": "company",
        "datetime": 1741697220,
        "headline": "Fidelity International Growth Fund Q4 2024 Review",
        "id": 133135940,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/93100504/image_93100504.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "For the final quarter of 2024, the fund's Retail Class shares returned\u00c2\u00a0-5.91%, outpacing the -9.08% result of the benchmark MSCI EAFE Growth Index (Net MA).",
        "url": "https://finnhub.io/api/news?id=0e8c45de57633994e7cee8e82e1ba4c102547743f2f43ae9736d1db79210780c"
    },
    {
        "category": "company",
        "datetime": 1741696980,
        "headline": "IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe",
        "id": 133194776,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The latest decision makes Ionis/AstraZeneca's Wainzua the only approved drug in the EU for ATTRv-PN that can be self-administered monthly via an auto-injector.",
        "url": "https://finnhub.io/api/news?id=01df41eeef2024ca5a0e9bd268f69df5e7448e3ca86f53436fafaae5ed44cdcd"
    },
    {
        "category": "company",
        "datetime": 1741694040,
        "headline": "Fidelity International Capital Appreciation Fund Q4 2024 Review",
        "id": 133135611,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1089284390/image_1089284390.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "For the final quarter of 2024, the fund returned -5.12%, outpacing the -7.58% result of the benchmark MSCI All Country World Index ex USA (Net MA) Index. Read more here.",
        "url": "https://finnhub.io/api/news?id=7343d032b1fb44c5f3d776c134e8fcc2bc84928a0b6cfbaa0fd180e81aaeb8af"
    },
    {
        "category": "company",
        "datetime": 1741648686,
        "headline": "AstraZeneca and Ionis win EU approval for ATTR polyneuropathy",
        "id": 133194777,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca and Ionis are intensifying their competition with Alnylam by securing an EU approval for Wainzua.",
        "url": "https://finnhub.io/api/news?id=9ddeb8dcdabc2f8257654d557c4dfa39d3d0eaefa4c89f0ecabfd008ac0a5386"
    },
    {
        "category": "company",
        "datetime": 1741601076,
        "headline": "AstraZeneca reports positive outcomes from trial of Imfinzi",
        "id": 133194778,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The perioperative treatment with Imfinzi plus FLOT showed improvement in event-free survival.",
        "url": "https://finnhub.io/api/news?id=df9547a42b105f47b7a01ae5e111f57e3d014ea2a0e693e80f49ec50756f4b4e"
    },
    {
        "category": "company",
        "datetime": 1741568520,
        "headline": "Fidelity Value Discovery Fund Q4 2024 Review",
        "id": 133114899,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1432028495/image_1432028495.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "For the three months ending December 31, 2024, the fund's Retail Class shares returned -3.41%, trailing the -1.94% return of the benchmark Russell 3000\u00c2\u00ae Value Index.",
        "url": "https://finnhub.io/api/news?id=da3cb6d6bb2994a879bb43bf701580e22d1855cb83830fb91c34d3da1094e5d3"
    },
    {
        "category": "company",
        "datetime": 1741352061,
        "headline": "AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients",
        "id": 133194779,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "On Friday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as a perioperative treatment for patients with resectable Stage II-IVA gastric and gastroesophageal junction (GEJ) cancers. The trial showed that perioperative treatment with Imfinzi in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improv",
        "url": "https://finnhub.io/api/news?id=b838cca2991858755f1368dad9ea94a565f6ddcc3d84d331e7348652c062a9cc"
    },
    {
        "category": "company",
        "datetime": 1741348800,
        "headline": "IMFINZI\u00ae (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers",
        "id": 133194780,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "WILMINGTON, Del., March 07, 2025--Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca\u2019s IMFINZI\u00ae (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS). Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before",
        "url": "https://finnhub.io/api/news?id=d9fc83512c725beaf8466edb1c3f3c7964f6caa057e2db2a2d877dac8753d658"
    },
    {
        "category": "company",
        "datetime": 1741302912,
        "headline": "Astrazeneca (AZN) Stock Moves -0.63%: What You Should Know",
        "id": 133194781,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "In the closing of the recent trading day, Astrazeneca (AZN) stood at $77.47, denoting a -0.63% change from the preceding trading day.",
        "url": "https://finnhub.io/api/news?id=3aea884228358d12c1208fa5043932a94ca9a530871c91869254ae3dde834547"
    },
    {
        "category": "company",
        "datetime": 1741264020,
        "headline": "Fidelity Equity-Income Fund Q4 2024 Review",
        "id": 133067285,
        "image": "",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=0a13f8130d74c1a89a6bf177bf7f3993a1d4aaaac63180e7ee3f3f4b75a323bf"
    },
    {
        "category": "company",
        "datetime": 1741245542,
        "headline": "Is AstraZeneca PLC (LON:AZN) Trading At A 45% Discount?",
        "id": 133194782,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Key Insights The projected fair value for AstraZeneca is UK\u00a3220 based on 2 Stage Free Cash Flow to Equity AstraZeneca's...",
        "url": "https://finnhub.io/api/news?id=b74b9aa0171873379ddd5d846bc23a668ca169d45b40465c8bdd0b2df62722eb"
    },
    {
        "category": "company",
        "datetime": 1741199139,
        "headline": "6 Ideal Buys From 14 'Safer' March Dividends On Bloomberg 2025 Watch List Of 50",
        "id": 133037570,
        "image": "",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=62c9fa80562fb3b63a94244d58759e68194e1fe48289f13d8b535cf0e6208e4f"
    },
    {
        "category": "company",
        "datetime": 1741185951,
        "headline": "What Trump's next batch of tariffs could mean for pharma industry",
        "id": 133185620,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The Trump administration has hinted at new tariffs that could impose a 25% tax on all pharmaceutical imports. Yahoo Finance senior health reporter Anjalee Khemlani joins the Morning Brief team in assessing how these policies could hit top companies. To watch more expert insights and analysis on the latest market action, check out more Morning Brief\u00a0here. This post was written by Luke Carberry Mogan.",
        "url": "https://finnhub.io/api/news?id=3ce9948723602633bbf6ecde2dfac2e420355bb6a1526831ed3674ec3f58aa55"
    },
    {
        "category": "company",
        "datetime": 1741158291,
        "headline": "Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges",
        "id": 133194784,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Compugen Ltd (CGEN) showcases promising developments in oncology treatments while navigating a decrease in annual revenue and a net loss for 2024.",
        "url": "https://finnhub.io/api/news?id=1eb4713f7f61e07b247da0e190599e63ec027cef9a495535aa60b02e2cc13bdc"
    },
    {
        "category": "company",
        "datetime": 1741158000,
        "headline": "AstraZeneca: A Big Pharma Blue Chip To Buy Now",
        "id": 133014320,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160089493/image_2160089493.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why AZN stock is a Buy.",
        "url": "https://finnhub.io/api/news?id=cfd8b986922238d8f18577141c30f3adeb0dfc858e0f3fb02005a45d28279824"
    },
    {
        "category": "company",
        "datetime": 1741088996,
        "headline": "EU set to approve AstraZeneca\u2019s Imfinzi-chemo combo for NSCLC",
        "id": 133194785,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The decision is supported by the outcomes from the AEGEAN trial.",
        "url": "https://finnhub.io/api/news?id=348d69ec7c4285fb7d8ff22f16397848eb521ce36efbf616f4b2e63ba256f33c"
    },
    {
        "category": "company",
        "datetime": 1741084244,
        "headline": "Daiichi Sankyo and AstraZeneca\u2019s Enhertu shows OS improvements in Phase III trial",
        "id": 133015497,
        "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2025/03/shutterstock_2306228027.jpg",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The trial enrolled 494 subjects in Europe, South America, and Asia.",
        "url": "https://finnhub.io/api/news?id=60ebb1495a6754218057d002c23069f7494691ad1567895a40dba4bdfafc12fb"
    },
    {
        "category": "company",
        "datetime": 1741005890,
        "headline": "Amgen\u00a0and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP",
        "id": 133194787,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The therapy is being developed jointly by AstraZeneca and Amgen.",
        "url": "https://finnhub.io/api/news?id=87da2807f010dfe7f32eb48c2275da8eb95546897b404cf79aad223848c47e2e"
    },
    {
        "category": "company",
        "datetime": 1740959818,
        "headline": "Tracking George Soros's 13F Portfolio - Q4 2024 Update",
        "id": 132947068,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451506045/image_1451506045.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "George Soros's 13F portfolio value decreased to $6.65B with 190 positions. Click here for a detailed analysis.",
        "url": "https://finnhub.io/api/news?id=63cecf62fd0d3c120f6a414dd5957f713005ca65fff2257e4947dca2edf77791"
    },
    {
        "category": "company",
        "datetime": 1740728400,
        "headline": "John Hancock Disciplined Value International Fund Q4 2024 Commentary",
        "id": 132905017,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183055316/image_183055316.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The John Hancock Disciplined Value International Fund underperformed the benchmark. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=9267ca11d71e7c9df5947f772d790572b805d550555f28edb058a60687f4ef4a"
    },
    {
        "category": "company",
        "datetime": 1740650974,
        "headline": "Why Novartis Remains A 'Buy' After Beating Expectations Again",
        "id": 132900099,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1795327693/image_1795327693.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read why I maintain my Buy rating on NVS.",
        "url": "https://finnhub.io/api/news?id=b49f962f627f1665d614d75198e399ec2db6f521a9c90fdc497f9d42746bdc43"
    },
    {
        "category": "company",
        "datetime": 1740591420,
        "headline": "Health Care Roundup: Market Talk",
        "id": 132927817,
        "image": "",
        "related": "AZN",
        "source": "DowJones",
        "summary": "Health Care Roundup: Market Talk",
        "url": "https://finnhub.io/api/news?id=b9069fb45c5334c34881d7a9e3855de1ab4217f27fc082eac099930247182663"
    },
    {
        "category": "company",
        "datetime": 1740585911,
        "headline": "AstraZeneca PLC (AZN): One of the Best Vaccine Stocks to Buy According to Hedge Funds",
        "id": 132879141,
        "image": "https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other best vaccine stocks to buy now. What Will Trump\u2019s Tariffs Mean for the Pharma Industry? On February 24, CNBC [\u2026]",
        "url": "https://finnhub.io/api/news?id=84ce5143e5bb809432bda61b89cd28a1ded10e35135e4bab83be66b1d7ee68c4"
    },
    {
        "category": "company",
        "datetime": 1740571462,
        "headline": "AstraZeneca breast cancer drug shows positive results, shares up",
        "id": 132879142,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Investing.com -- AstraZeneca (NASDAQ:AZN) announced on Wednesday that its experimental breast cancer treatment, camizestrant, helped extend survival without disease progression in patients with an advanced form of the illness during a late-stage clinical trial.",
        "url": "https://finnhub.io/api/news?id=cf2b5017e726bbb9c1db31ab374cff48dd248ada7ae3d77f4ddfb4a92198d6fd"
    },
    {
        "category": "company",
        "datetime": 1740571200,
        "headline": "Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial",
        "id": 132879143,
        "image": "https://s.yimg.com/ny/api/res/1.2/qP9zCNUC6h89Z69JJ19WUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zOTY-/https://media.zenfs.com/en/business-wire.com/6be9afe7b91fa8bdfa9491977af3fbcc",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "WILMINGTON, Del., February 26, 2025--Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca\u2019s camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS). The trial evaluated switching to the camizestrant combination versus continuing",
        "url": "https://finnhub.io/api/news?id=ecd75ca45d0a7dc112fc9613877782414fb4cee6fa6ab8891187719f69b147d0"
    },
    {
        "category": "company",
        "datetime": 1740561344,
        "headline": "Merck's Oncology Strength: Beating Wall Street Again",
        "id": 132878313,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/151810706/image_151810706.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.",
        "url": "https://finnhub.io/api/news?id=48cc045b6210dbf5fc551d979a18cc216581d878f6df5c6d273d0c4b6879a62b"
    },
    {
        "category": "company",
        "datetime": 1740540360,
        "headline": "AstraZeneca\u2019s Breast Cancer Drug Shows Positive Results In Late-Stage Trial",
        "id": 132927818,
        "image": "",
        "related": "AZN",
        "source": "DowJones",
        "summary": "AstraZeneca\u2019s Breast Cancer Drug Shows Positive Results In Late-Stage Trial",
        "url": "https://finnhub.io/api/news?id=40f1a47ecbcd6098c0282417c92494c611916e9d4f4db663bdefc0c09782d8d1"
    },
    {
        "category": "company",
        "datetime": 1740436038,
        "headline": "AstraZeneca PLC (AZN): A High Growth Mega Cap Stock You Can Buy and Hold for the Next 5 Years",
        "id": 132879144,
        "image": "https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other high growth mega cap stocks. Exactly 5 years ago, the world struggled to deal with [\u2026]",
        "url": "https://finnhub.io/api/news?id=440d9534edb581bfc9e63f1b9685d669f42e368662b0cba54d23831bbeebaa44"
    },
    {
        "category": "company",
        "datetime": 1740405000,
        "headline": "Hartford International Equity Fund Q4 2024 Commentary",
        "id": 132865183,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/96502248/image_96502248.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Hartford International Equity Fund (I share) outperformed the MSCI ACWI ex-US during the quarter. Read more here.",
        "url": "https://finnhub.io/api/news?id=108792129033a93d9670d1b877fb06c35ff05c685aac19f8b82bf264216dc1da"
    },
    {
        "category": "company",
        "datetime": 1740392127,
        "headline": "Compass Therapeutics: Good Execution, Major Catalysts Ahead",
        "id": 132864016,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688767071/image_1688767071.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Explore Compass Therapeutics' tovecimig trials, upcoming Phase 3 BTC data, and market insights.",
        "url": "https://finnhub.io/api/news?id=b1469714b8e1c61deb53e8fba05f5cf8f889f5b64ca602e00bfacb2523690455"
    },
    {
        "category": "company",
        "datetime": 1740387600,
        "headline": "Leading Healthcare Institutions Adopt MSK-ACCESS\u00ae for Liquid Biopsy Testing",
        "id": 132879145,
        "image": "https://media.zenfs.com/en/prnewswire.com/7af8bf13f8f939ef861dc0027929881b",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS\u00ae powered with SOPHiA DDM\u2122 and MSK-IMPACT\u00ae powered with SOPHiA DDM\u2122. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.",
        "url": "https://finnhub.io/api/news?id=15e320592cc4d2c1e9abd54bd52485089dcbc8b54b1491bd8105dd336134e348"
    },
    {
        "category": "company",
        "datetime": 1740284542,
        "headline": "AstraZeneca PLC (AZN): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts",
        "id": 132879146,
        "image": "https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other pharmaceutical stocks. The Evolving Landscape of Healthcare and Biopharma Innovation Almost no other industry goes as far as the phrase \u201cdefensive\u201d [\u2026]",
        "url": "https://finnhub.io/api/news?id=987bd9005b0c8e636627a33896471133a925e4e0eb6e0c7fb322f777b493d08e"
    },
    {
        "category": "company",
        "datetime": 1740221220,
        "headline": "3 Magnificent Growth Stocks to Buy Right Now",
        "id": 132879148,
        "image": "https://g.foolcdn.com/editorial/images/808416/couple-looking-at-laptop.jpg",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "In a sense, every investor is a growth investor.  Three Motley Fool contributors think they've found magnificent growth stocks to buy right now.  Here's why they picked AstraZeneca (NASDAQ: AZN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).",
        "url": "https://finnhub.io/api/news?id=857b55d80b1ae41f3d04a81f3a825a00c0a583c86c7037125da7fb0a016b242e"
    },
    {
        "category": "company",
        "datetime": 1740211994,
        "headline": "Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug",
        "id": 132833341,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth.",
        "url": "https://finnhub.io/api/news?id=f49f82d88ee774759cfd86e64cf88a28fa806fd0621b66042831040269a658eb"
    },
    {
        "category": "company",
        "datetime": 1740086876,
        "headline": "AstraZeneca PLC (AZN): Among the Best Global Stocks to Buy According to Hedge Funds",
        "id": 132879150,
        "image": "https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently published a list of 12 Best Global Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best global stocks to buy according to hedge funds. The United States has long been a magnet for global businesses seeking [\u2026]",
        "url": "https://finnhub.io/api/news?id=c4908c9ff5814a1330852088fd0816f2c17928fdf56c942faf34cab040444d13"
    },
    {
        "category": "company",
        "datetime": 1740085323,
        "headline": "FibroGen sells China unit to AstraZeneca for $160m",
        "id": 132879152,
        "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/02/GettyImages-1189506707-e1740072318569.jpg",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney disease.",
        "url": "https://finnhub.io/api/news?id=5f61ff575ddf6ef3741d7ef8549fb27c880f937a6f70339ac74f62343a87357e"
    },
    {
        "category": "company",
        "datetime": 1740072300,
        "headline": "AstraZeneca PLC ADR rises Thursday, outperforms market",
        "id": 132854577,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca PLC ADR rises Thursday, outperforms market",
        "url": "https://finnhub.io/api/news?id=c84ca952f666a0ac47b6c240d04f5611706dc59ff7071f2eb4a6950e7cb54e62"
    },
    {
        "category": "company",
        "datetime": 1740068280,
        "headline": "AstraZeneca Rises Almost 9% in a Month: How to Play the Stock",
        "id": 132879153,
        "image": "https://media.zenfs.com/en/zacks.com/7f0fb6bf42f42cec0a78ad3110808365",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.",
        "url": "https://finnhub.io/api/news?id=03606370baf4bea1ec122dbc2821e7009210afa79ac77e04fab9bcae0484b6b9"
    },
    {
        "category": "company",
        "datetime": 1740068100,
        "headline": "Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus",
        "id": 132879154,
        "image": "https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "IONS reports better-than-expected top and bottom-line numbers for the fourth quarter.",
        "url": "https://finnhub.io/api/news?id=db58049e27b15510390b54cadf32a3c6aa3f9b0d6e825ed557faa8ba4b4d5e1e"
    },
    {
        "category": "company",
        "datetime": 1740060360,
        "headline": "Madison International Stock Fund Q4 2024 Investment Strategy Letter",
        "id": 132818121,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193247114/image_2193247114.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Madison International Stock Fund outperformed the MSCI ACWI ex-US index in the final quarter of 2024. Read more here.",
        "url": "https://finnhub.io/api/news?id=b9dba4d1b48a52eb511759aac8974e2d0cdf17408dedb7c20311f3f6d7292d6c"
    },
    {
        "category": "company",
        "datetime": 1740058161,
        "headline": "FibroGen to Sell China Unit to AstraZeneca for $160 Million",
        "id": 132879155,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "FibroGen (FGEN) said Thursday it has agreed to sell its China subsidiary to AstraZeneca (AZN) for ab",
        "url": "https://finnhub.io/api/news?id=c41e514233438cf8900ebaf259290479a9e91b59dad8cedc70721a1a161828dd"
    },
    {
        "category": "company",
        "datetime": 1740055699,
        "headline": "Here\u2019s Why AstraZeneca PLC (AZN) Traded Lower in Q4",
        "id": 132879156,
        "image": "https://media.zenfs.com/en/insidermonkey.com/7ca66c8f2db4aa9396371cdb44897ceb",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Baron Funds, an investment management company, released its \u201cBaron Health Care Fund\u201d fourth quarter 2024 investor letter. The Fund performed roughly in line with the Benchmark, during a challenging quarter for the larger health care industry. A copy of the letter can be downloaded here. The fund declined 9.58% (Institutional Shares) in the quarter compared [\u2026]",
        "url": "https://finnhub.io/api/news?id=1da6c51f43967a55fa81fe035b3930f06bf57a51d6c27aef05c293b3df21e418"
    },
    {
        "category": "company",
        "datetime": 1740051625,
        "headline": "AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal",
        "id": 132879157,
        "image": "https://media.zenfs.com/en/reuters-finance.com/1729e46d7ec14486c806834b51feda8d",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The deal comes at a time when the Anglo-Swedish pharma company is facing a string of investigations in the country, AstraZeneca's biggest international market that accounted for 12% of 2024 sales, following heavy investments in the region.  AstraZeneca in 2023 signed several licensing deals with Chinese companies and bought Suzhou-headquartered Gracell Biotechnologies for $1.2 billion.  Earlier this month, the company reassured investors that the impact of several probes in China could be minor.",
        "url": "https://finnhub.io/api/news?id=2c361a241a971514a2ee7d5665085a8d7a34b859f37e1df953fd123d81b8147a"
    },
    {
        "category": "company",
        "datetime": 1740048900,
        "headline": "AstraZeneca deepens China presence with FibroGen deal",
        "id": 132879158,
        "image": "https://imgproxy.divecdn.com/a3a3JEBTriJp7MhK30t25XXjSWuXl9rJh7ixyK3ahcg/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy01NzYxMTA0My5qcGc=.webp",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca\u2019s foothold in China while the company works\u00a0through government\u00a0investigations into its business practices there.",
        "url": "https://finnhub.io/api/news?id=f19dd78d2d8aa502d6ebdaa176e9c81dc0c07defb4b30d9fb09bc905b459e641"
    },
    {
        "category": "company",
        "datetime": 1740042977,
        "headline": "Q4 2024 Ionis Pharmaceuticals Inc Earnings Call",
        "id": 132879159,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Q4 2024 Ionis Pharmaceuticals Inc Earnings Call",
        "url": "https://finnhub.io/api/news?id=d162a8d077c04b54eae15094e4c306fc0668f4dc66f0165a2b5de7b17ee998e7"
    },
    {
        "category": "company",
        "datetime": 1740039581,
        "headline": "Luxury hotels group Firmdale has sold 20% stake to Swedish pharma tycoon",
        "id": 132879160,
        "image": "https://static.standard.co.uk/s3fs-public/thumbnails/image/2018/10/26/14/crosby-street-hotel.jpg?width=1200&auto=webp&quality=75",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "It is the first time that a significant stake in Firmdale has been sold to an external investor since it was founded in 1985 by husband and wife team Tim and Kit Kemp.",
        "url": "https://finnhub.io/api/news?id=2fc5f49e1c16e077d825de319d0f6e3e16504bff5ce4d526253f299544858578"
    },
    {
        "category": "company",
        "datetime": 1740032361,
        "headline": "AstraZeneca Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags",
        "id": 132879161,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca ( LON:AZN ) Full Year 2024 Results Key Financial Results Revenue: US$54.1b (up 18% from FY 2023). Net...",
        "url": "https://finnhub.io/api/news?id=d143b90022af4ddc6bcf4cdd6632d5833d5d1a066f04a9de2eee9b1a1b328880"
    },
    {
        "category": "company",
        "datetime": 1739985900,
        "headline": "AstraZeneca PLC ADR falls Wednesday, underperforms market",
        "id": 132822097,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca PLC ADR falls Wednesday, underperforms market",
        "url": "https://finnhub.io/api/news?id=6caa9a9d6369b21370ecc24f0901fafdf687ee3843ad78b4043dea32b29acf96"
    },
    {
        "category": "company",
        "datetime": 1739976042,
        "headline": "Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval",
        "id": 132790634,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1914834329/image_1914834329.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Ionis Pharmaceuticals beats Q4 earnings, eyes sHTG market with TRYNGOLZA. Strong pipeline and cash position make it a must-watch. Read more on IONS stock here.",
        "url": "https://finnhub.io/api/news?id=c147bb3682f8801342414e0c14009394d6ffbd5f6cd03234c4043a82013f96c7"
    },
    {
        "category": "company",
        "datetime": 1739970048,
        "headline": "AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold",
        "id": 132790312,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250576655/image_1250576655.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed clinical results create uncertainty.",
        "url": "https://finnhub.io/api/news?id=3e0857b57c89afb2552db938b675a997e4ef7b26528ac3132cc1f7b1dd262ed4"
    },
    {
        "category": "company",
        "datetime": 1739901626,
        "headline": "AstraZeneca boss takes home \u00a315m pay packet after profits rise",
        "id": 132879162,
        "image": "https://s.yimg.com/ny/api/res/1.2/upF1cpMWnOOtF_pzvxO8xA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/snappa.ukfinance/ec8bbc144b5c52d20205a2985c119f76",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The Cambridge-based pharmaceutical company behind a variety of medicines paid its chief executive Pascal Soriot \u00a314.7 million in 2024.",
        "url": "https://finnhub.io/api/news?id=7f6409186ecd26babaa55b10f03c8784943194655b96e1624318bb9cf9e31b0a"
    },
    {
        "category": "company",
        "datetime": 1739885220,
        "headline": "American Century International Growth Fund Q4 2024 Commentary",
        "id": 132779047,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/93100504/image_93100504.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Non-U.S. developed markets stocks finished the fourth quarter lower. Political uncertainty in some of the largest European economies has diminished their growth outlook.",
        "url": "https://finnhub.io/api/news?id=c0de1ca7b2164a7721ca697580e3fe9e50620552a89def40411751ded3a5d94d"
    },
    {
        "category": "company",
        "datetime": 1739881729,
        "headline": "AstraZeneca (LON:AZN) Is Posting Promising Earnings But The Good News Doesn\u2019t Stop There",
        "id": 132879163,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/bba95900ab96866c17a285be850152bf",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca PLC ( LON:AZN ) announced a healthy earnings result recently, and the market rewarded it with a strong...",
        "url": "https://finnhub.io/api/news?id=d192c3794804504f6f7d7b35faf172d80fa3690274d8ffbd6ce5d0f277b122d5"
    },
    {
        "category": "company",
        "datetime": 1739845293,
        "headline": "GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'",
        "id": 132765945,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/164210757/image_164210757.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's rating from Buy to Strong Buy.",
        "url": "https://finnhub.io/api/news?id=79f9d082cf625de8b867702d2868dea83fc96c4cb55e6dce4daad22a8c0a5645"
    },
    {
        "category": "company",
        "datetime": 1739780400,
        "headline": "Parnassus Value Equity Fund Q4 And 2024 Annual Investment Commentary",
        "id": 132749723,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159126735/image_2159126735.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Parnassus Value Equity Fund returned -1.48% (net) for Q4 2024, outperforming the Russell 1000 Value Index\u00e2\u0080\u0099s -1.98%. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=9158e1247f9718d3e8a1093f7e7de1e04d5e89f133d52c6d4879748505ed7f82"
    },
    {
        "category": "company",
        "datetime": 1739778900,
        "headline": "Parnassus Growth Equity Fund Q4 And 2024 Annual Investment Commentary",
        "id": 132748104,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2071111658/image_2071111658.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Parnassus Growth Equity Fund returned 4.85% (net) for Q4 2024, underperforming the Russell 1000 Growth Index\u00e2\u0080\u0099s 7.07%. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=0e91fa81ce79a6a058f2186406389749201e7c0b0c8e23f98408dde776ffd009"
    },
    {
        "category": "company",
        "datetime": 1739742843,
        "headline": "Why Regeneron's Price May Soon Break Out",
        "id": 132742765,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398811731/image_1398811731.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top pick for long-term investors.",
        "url": "https://finnhub.io/api/news?id=d5af37c15f7937cb7659c25bbaefc15e6d819270430ea1e30992e3c141a5a315"
    },
    {
        "category": "company",
        "datetime": 1739480280,
        "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q4 2024 Commentary",
        "id": 132709614,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172483014/image_172483014.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Portfolio returned -10.75% (gross) and the MSCI World Health Care IndexSM returned -11.32%. Read more here.",
        "url": "https://finnhub.io/api/news?id=8d306981723ae6baaa27a41df72a2ad77528d2ff9fae45eee20d34b6483d2dcd"
    },
    {
        "category": "company",
        "datetime": 1739441100,
        "headline": "Janus Henderson European Focus Fund Q4 2024 Commentary",
        "id": 132701347,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/612861656/image_612861656.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Fund returned -8.89% and the MSCI Europe NR Index returned -9.74%. We see catalysts that could help lift the gloom hanging over European equity markets.",
        "url": "https://finnhub.io/api/news?id=ec354f94e9fe56096f1699d101f2987a86d880b2a8ec64bdd8696efbd63251a8"
    },
    {
        "category": "company",
        "datetime": 1739392800,
        "headline": "Janus Henderson Global Life Sciences Fund Q4 2024 Commentary",
        "id": 132698753,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205585/image_1322205585.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=10b10afe2a805029d7ce2f9c8b1ec10ce14300270ce9d50ee7971586c5474449"
    },
    {
        "category": "company",
        "datetime": 1739281260,
        "headline": "Invesco Dividend Income Fund Q4 2024 Commentary",
        "id": 132667895,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365758819/image_1365758819.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The fund is balanced across sectors and industries, with a focus on long-term growth areas and companies with sustainable free cash flow and healthy balance sheets.",
        "url": "https://finnhub.io/api/news?id=4e27fb9f750361b2f5426f81fcc9467cb918c136076824af65d00c2b6470f80c"
    },
    {
        "category": "company",
        "datetime": 1739269800,
        "headline": "Invesco International Diversified Fund Q4 2024 Commentary",
        "id": 132658190,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453953453/image_1453953453.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The fund\u00e2\u0080\u0099s underlying portfolios are biased toward quality companies with favorable long-term prospects.",
        "url": "https://finnhub.io/api/news?id=94d030207dce70d5c358c47cdc4ef67f662b9a51d0b625ff26278887d753c0df"
    },
    {
        "category": "company",
        "datetime": 1739267520,
        "headline": "Invesco Developing Markets Fund Q4 2024 Commentary",
        "id": 132658073,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159126735/image_2159126735.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Invesco Developing Markets Fund Class A shares outperformed the MSCI EM Index. Stock selection in the consumer discretionary sector added to relative return.",
        "url": "https://finnhub.io/api/news?id=d820a97b3fa082556eb63048b90df3376f4a938920f9abdf78bd8e95de8d0c72"
    },
    {
        "category": "company",
        "datetime": 1739150100,
        "headline": "ClearBridge Global Value Improvers Strategy Q4 2024 Commentary",
        "id": 132630188,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1335295813/image_1335295813.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The ClearBridge Global Value Improvers Strategy outperformed its MSCI World Value benchmark during Q4 2024. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=04a6cc6384e5428124ad5d3acbfa978d0323850881a377f00981946ec584cad3"
    },
    {
        "category": "company",
        "datetime": 1739086500,
        "headline": "Fidelity Diversified International Fund Q4 2024 Review",
        "id": 132626564,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912015114/image_912015114.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "For the fourth quarter, the fund's Retail Class shares returned\u00c2\u00a0-7.11%, outpacing the -8.09% result of the benchmark, the MSCI EAFE Index. Read more here.",
        "url": "https://finnhub.io/api/news?id=bbeeaa5634f2a67e2a58841e6070f9750b7a11f5fc2f4821952532443e1a8a5a"
    },
    {
        "category": "company",
        "datetime": 1738857795,
        "headline": "AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.",
        "id": 132625680,
        "image": "",
        "related": "AZN",
        "source": "DowJones",
        "summary": "AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.",
        "url": "https://finnhub.io/api/news?id=7c45b02494e0aa7989d72833ac80a05fbeeabe9eb8d9e0886234d0ff8ab328af"
    },
    {
        "category": "company",
        "datetime": 1738844219,
        "headline": "AstraZeneca PLC (AZN) Q4 2024 Earnings Call Transcript",
        "id": 132574712,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "AstraZeneca PLC (NASDAQ:AZN) Q4 2024 Earnings Conference Call February 6, 2025 6:00 AM ETCompany ParticipantsPascal Soriot \u00e2\u0080\u0093 Executive Director and Chief...",
        "url": "https://finnhub.io/api/news?id=76698cf847a981a9420b2c3fefc4b5634aa22b740c789751b49a8f9a150c675b"
    },
    {
        "category": "company",
        "datetime": 1738838590,
        "headline": "AstraZeneca PLC 2024 Q4 - Results - Earnings Call Presentation",
        "id": 132573121,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The following slide deck was published by AstraZeneca PLC in conjunction with their 2024 Q4 earnings call.",
        "url": "https://finnhub.io/api/news?id=3a62bc9c62a65803e5b13187336e311108f661aa471e98857b0e8cd64cc53be0"
    },
    {
        "category": "company",
        "datetime": 1738821660,
        "headline": "AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China",
        "id": 132625681,
        "image": "",
        "related": "AZN",
        "source": "DowJones",
        "summary": "AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China",
        "url": "https://finnhub.io/api/news?id=875eb851aa882e35970dd92c3893ecc461599dc90b27f9adc4ee54f717799465"
    },
    {
        "category": "company",
        "datetime": 1738755370,
        "headline": "Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data",
        "id": 132563236,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2176324258/image_2176324258.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients with PH-HFpEF. Explore more details here.",
        "url": "https://finnhub.io/api/news?id=c2c0632550887f310d31450bf5608d03733354ea6bc037645aac0a97171049b3"
    },
    {
        "category": "company",
        "datetime": 1738667940,
        "headline": "AstraZeneca Sales, Core EPS Seen Rising -- Earnings Preview",
        "id": 132625700,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca Sales, Core EPS Seen Rising -- Earnings Preview",
        "url": "https://finnhub.io/api/news?id=d694cb293eba75ee779c164dcca13ef388e31b4f0c69a2f54013081dac5be161"
    },
    {
        "category": "company",
        "datetime": 1738603380,
        "headline": "AstraZeneca PLC ADR falls Monday, underperforms market",
        "id": 132625701,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca PLC ADR falls Monday, underperforms market",
        "url": "https://finnhub.io/api/news?id=b18f39e528ffd2395758fc4e2e84a47f52db4d749d4b2aaa57057e7e6004fa6e"
    },
    {
        "category": "company",
        "datetime": 1738472729,
        "headline": "ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data",
        "id": 132514154,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "ORIC's ORIC-533 was promising but failed in trials, leaving ORIC-114 and ORIC-944 as key pipeline assets. Read why I am neutral on ORIC stock.",
        "url": "https://finnhub.io/api/news?id=b8adc832885d57ebc67b473c3828e685bd6413a80d2eedee4116d146c10d33b7"
    },
    {
        "category": "company",
        "datetime": 1738321002,
        "headline": "Buy 1 Safer Ideal January Dog Of 35 Barron's Pro-Picked 2025 Dividends",
        "id": 132505458,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177572660/image_2177572660.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Get insights into top dividend stock picks for 2025 from Barron\u00e2\u0080\u0099s Roundtable, with potential gains ranging from 19.46% to 35.09%.",
        "url": "https://finnhub.io/api/news?id=2340d202ff7e78e34ea37ad064cf35a4d5941d179d166c4d766d135b021fa9a3"
    },
    {
        "category": "company",
        "datetime": 1738228500,
        "headline": "ClearBridge International Growth ADR Portfolios Q4 2024 Commentary",
        "id": 132499591,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1148772285/image_1148772285.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The benchmark MSCI EAFE Index declined 8.11% in the quarter while the MSCI Emerging Markets Index fell 8.01%. Read more here.",
        "url": "https://finnhub.io/api/news?id=1e0b9cb4b5ae426a2c899785c70eefd739d3ef520e80daf74113941cd7091db2"
    },
    {
        "category": "company",
        "datetime": 1738190580,
        "headline": "Templeton Foreign Fund Q4 2024 Commentary",
        "id": 132496190,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/589422272/image_589422272.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Signals from the US Federal Reserve that it intends to be cautious about further rate cuts helped drive global equities collectively lower in December 2024.",
        "url": "https://finnhub.io/api/news?id=4230cf78e54102d08791cf12c8556dbbe3cd6834093e59bd324186455f2941b3"
    },
    {
        "category": "company",
        "datetime": 1738153038,
        "headline": "BGY: Strong Dollar Weighs On International Markets, But Don't Ignore Them",
        "id": 132493665,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304034608/image_1304034608.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The BlackRock Enhanced International Dividend Trust offers high income and international diversification. U.S. equities are richly valued, making diversification through this CEF appealing.",
        "url": "https://finnhub.io/api/news?id=06fa7e9fd9399df5178395383a4dfdeae4f36c9eeae80a7e265897750fc6601e"
    },
    {
        "category": "company",
        "datetime": 1738127460,
        "headline": "Franklin International Growth Fund Q4 2024 Commentary",
        "id": 132491347,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/875074102/image_875074102.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Unlike in the U.S., where moderating inflation has been accompanied by resilient GDP growth, Europe and the U.K. continue to face recession risks. Read more here.",
        "url": "https://finnhub.io/api/news?id=65c3cb19890fcca91720b1a7aa24e100e5295e539de00b5c2b04661624de7e2f"
    },
    {
        "category": "company",
        "datetime": 1738123500,
        "headline": "Baron International Growth Fund Q4 2024 Shareholder Letter",
        "id": 132491053,
        "image": "",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=8a7f7cb3561be7e340beef1128add1adfea5170814650c5376e88e758fb90c06"
    },
    {
        "category": "company",
        "datetime": 1738004340,
        "headline": "AstraZeneca Receives FDA Approval for Enhertu Breast Cancer Treatment",
        "id": 132625702,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca Receives FDA Approval for Enhertu Breast Cancer Treatment",
        "url": "https://finnhub.io/api/news?id=2e20cd1577e589467a331274d74f95073884f12dae935e7adb972ac2fa082ae2"
    },
    {
        "category": "company",
        "datetime": 1737901320,
        "headline": "ClearBridge International Growth ADR ESG Portfolios Q4 2024 Commentary",
        "id": 132474834,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/875074102/image_875074102.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The stronger US dollar and negative sentiment over the current state of political affairs in Europe also weighed on the largest developed markets. Read more here.",
        "url": "https://finnhub.io/api/news?id=8ba3b0cbd1dc3af65aca4c065f227c9580f0be30c7b7dd236f2b660563899683"
    },
    {
        "category": "company",
        "datetime": 1737792000,
        "headline": "5 Best CEFs This Month For Nearly 10% Yield (January 2025)",
        "id": 132468888,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310121198/image_1310121198.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Discover high-yield closed-end funds for income investors with reasonable total returns. Click for our process of winnowing out the best CEFS this month.",
        "url": "https://finnhub.io/api/news?id=197c5be575be03a4b9586b3090506ccae90f12a685d42c55c0010fb160219701"
    },
    {
        "category": "company",
        "datetime": 1737644040,
        "headline": "AstraZeneca to Invest C$820 Million to Move to Larger Toronto Office",
        "id": 132625703,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca to Invest C$820 Million to Move to Larger Toronto Office",
        "url": "https://finnhub.io/api/news?id=90179e93f28c640e7b62bfb5f23e752e723aca1134f08fb3c4abffe9a3b1dbc4"
    },
    {
        "category": "company",
        "datetime": 1737639382,
        "headline": "AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating",
        "id": 132449871,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429764/image_107429764.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company\u00e2\u0080\u0099s future looks bright.",
        "url": "https://finnhub.io/api/news?id=b0bffa5a9ae5c47a255e185aa2cf65897e628d26de0c5f6cfe30db3a2a88b556"
    },
    {
        "category": "company",
        "datetime": 1737548946,
        "headline": "3 Biotech Stocks With Notable Insider Buying",
        "id": 132443265,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289907650/image_1289907650.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Despite a 15% drop in the SPDR S&P Biotech ETF, insider buying presents opportunities. Read why these small and mid-cap biotech stocks are worth a closer look.",
        "url": "https://finnhub.io/api/news?id=e1571b36b59d0619f7670669fc1f1d202e31d652efb4ae605207fc93882e12aa"
    },
    {
        "category": "company",
        "datetime": 1737543300,
        "headline": "Baron Health Care Fund Q4 2024 Shareholder Letter",
        "id": 132442862,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Baron Health Care Fund retreated in the fourth quarter of 2024, in line with its benchmark, the Russell 3000 Health Care Index. Read more here.",
        "url": "https://finnhub.io/api/news?id=0271890740cb4d946feb67364f9ef0cbee944c4e8517254a2ede741d5201d864"
    },
    {
        "category": "company",
        "datetime": 1737465892,
        "headline": "5 Ideal Buys From 14 'Safer' January Dividends On Bloomberg 2025 Watch List Of 50",
        "id": 132437460,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/535538189/image_535538189.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Bloomberg Intelligence analysts identified 50 watchable firms for 2025, focusing on catalysts like new leadership and more. Click here for more information.",
        "url": "https://finnhub.io/api/news?id=2dc6401e371368e7d981387fd09f7ee8429e6555e60f7dd5267c9d3735c5cb71"
    },
    {
        "category": "company",
        "datetime": 1737440400,
        "headline": "Artisan International Fund Q4 2024 Commentary",
        "id": 132435250,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/96502248/image_96502248.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The portfolio delivered double-digit returns in 2024, outperforming the single-digit gains of the MSCI EAFE and the MSCI AC World ex USA Indices, the primary and secondary benchmarks.",
        "url": "https://finnhub.io/api/news?id=a882c94f2f19e1609a663b946511e5023e5ab16ffb9cfad97704e06269830c42"
    },
    {
        "category": "company",
        "datetime": 1737317924,
        "headline": "Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension",
        "id": 132427206,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1719538574/image_1719538574.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. Read why I feel MLYS stock is a good speculative Buy.",
        "url": "https://finnhub.io/api/news?id=353116c23779efcadc9e2a7100d5ac0cd9f0402be1224d6f807094768e92dfe6"
    },
    {
        "category": "company",
        "datetime": 1737305685,
        "headline": "Top 4 Immunology Stocks Poised For Growth In 2025",
        "id": 132426490,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413108793/image_1413108793.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Discover the latest trends and developments in the global immunology drugs market, along with four promising stocks to watch for potential investments.",
        "url": "https://finnhub.io/api/news?id=89d92fb4873b2558c4d0f5f75610a8a4ee6050f99c0d8d2410f07380589e1d07"
    },
    {
        "category": "company",
        "datetime": 1737179168,
        "headline": "AstraZeneca: Diverse Clinical Pipeline Meeting Future Demand, In Undervalued Sector",
        "id": 132419501,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1583178742/image_1583178742.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "We are initiating coverage of AstraZeneca with a buy rating, highlighting diverse solutions and new projects, despite weaker profit margin and legal risks. See more.",
        "url": "https://finnhub.io/api/news?id=e95a7a9239cea432bab3aa21bf3b498757fce511c1893c4e12e51569dacb79bd"
    },
    {
        "category": "company",
        "datetime": 1737138540,
        "headline": "AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway",
        "id": 132625704,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway",
        "url": "https://finnhub.io/api/news?id=95eaac0c80314d9dd471cee749cae2a5d67d768ee28928a83167e52b8e443866"
    },
    {
        "category": "company",
        "datetime": 1736827500,
        "headline": "Mawer Investment Management Q4 2024 Quarterly Update",
        "id": 132392313,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163730037/image_2163730037.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Global central banks continued to ease this quarter, though the pace of easing varied. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=eb3c9d01a0e3e4d0e687644b5609193c2889554d59153afbc8e9cbe3a4a3e999"
    },
    {
        "category": "company",
        "datetime": 1736791802,
        "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
        "id": 132390023,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1886168184/image_1886168184.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
        "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835"
    },
    {
        "category": "company",
        "datetime": 1736747815,
        "headline": "SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate",
        "id": 132386392,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177260462/image_2177260462.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024. See why I rate SWTX stock a strong buy.",
        "url": "https://finnhub.io/api/news?id=8a4833b7c0dbcdf2a59ef3d7d12e8877cadca798aa4e02c468e92d343c93357c"
    },
    {
        "category": "company",
        "datetime": 1736579106,
        "headline": "Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade",
        "id": 132377273,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2188209231/image_2188209231.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.",
        "url": "https://finnhub.io/api/news?id=ca252f8d2f0175b19346cf4e77df62c7d3f891418ce1cd2aea88d914a31354d2"
    },
    {
        "category": "company",
        "datetime": 1736482200,
        "headline": "ClearBridge International Growth EAFE Strategy Q4 2024 Commentary",
        "id": 132359398,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1488290418/image_1488290418.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "During the fourth quarter, the ClearBridge International Growth EAFE Strategy outperformed its MSCI EAFE Index benchmark. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=3fac7d8e36cde39051566e5a8b19d6a038352ee417ec480dcd8a4c97d1bdfb15"
    },
    {
        "category": "company",
        "datetime": 1736480293,
        "headline": "High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower",
        "id": 132358957,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1269090428/image_1269090428.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for risk-tolerant investors. See more here.",
        "url": "https://finnhub.io/api/news?id=cbec3b655141026a8080e3cb9f043dc126b78def306bad017e0bb5407a84c48a"
    },
    {
        "category": "company",
        "datetime": 1736423100,
        "headline": "3 Cheap Growth Stocks to Buy in 2025",
        "id": 132347094,
        "image": "https://g.foolcdn.com/editorial/images/802840/businessperson-giving-a-presentation.jpg",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term.  For long-term investors, now may be a good time to reevaluate the contents of your portfolio to see if it's worth potentially selling off some of your recent high performers and swapping in some cheaper growth stocks instead.  Three growth stocks that look particularly cheap right now are AstraZeneca (NASDAQ: AZN), Uber Technologies (NYSE: UBER), and Zoom Communications (NASDAQ: ZM).",
        "url": "https://finnhub.io/api/news?id=58363973108aecb67a67a65b879c1758074539262d5237739317e363d20efc4a"
    },
    {
        "category": "company",
        "datetime": 1736347513,
        "headline": "Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term",
        "id": 132318805,
        "image": "https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
        "url": "https://finnhub.io/api/news?id=76b8018bc72f22cea055cb3dd2d18e3b2c45b539b23a63e5482cf1bd7a88ef76"
    },
    {
        "category": "company",
        "datetime": 1736249479,
        "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
        "id": 132302431,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
        "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0"
    },
    {
        "category": "company",
        "datetime": 1736178017,
        "headline": "Why Is AstraZeneca PLC (NASDAQ:AZN) Among the Best FTSE Dividend Stocks to Buy Now?",
        "id": 132289897,
        "image": "https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 10 Best FTSE Dividend Stocks To Buy Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other FTSE dividend stocks. Goldman Sachs Research predicts moderate growth for the UK economy in 2025, with GDP rising 1.2%. That is slightly [\u2026]",
        "url": "https://finnhub.io/api/news?id=6acd87d64b49e6e8783c89632ceb543c60002f3b39948dcd3f3035e14e80f441"
    },
    {
        "category": "company",
        "datetime": 1736170920,
        "headline": "AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?",
        "id": 132289898,
        "image": "https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates with blockbuster potential.",
        "url": "https://finnhub.io/api/news?id=ba1d6d1ec3936a722a87122120f4a8b8a2a4721733c844e19f355ef4a04767e4"
    },
    {
        "category": "company",
        "datetime": 1736085864,
        "headline": "AstraZeneca: Uncertainty Ahead, Neutral Rating Confirmed.",
        "id": 132279597,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1287552192/image_1287552192.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Analysis of AstraZeneca's market potential, including China and IRA impacts, and the importance of key readouts in 2025 for success.",
        "url": "https://finnhub.io/api/news?id=eb59cff5d841abb6037670dd5ac2540a73c8c905e21ccdca6d4e3f2124c9cbaa"
    },
    {
        "category": "company",
        "datetime": 1736062200,
        "headline": "Tectonic Therapeutic: Protein Engineering Platform For GPCRs",
        "id": 132277466,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1543488776/image_1543488776.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm bullish on TECX stock.",
        "url": "https://finnhub.io/api/news?id=fb0d90e895ed6e36cb9be939f68e942b3386a294f934ae887312ba22311dec53"
    },
    {
        "category": "company",
        "datetime": 1735987320,
        "headline": "Better Buy: Novo Nordisk vs. AstraZeneca",
        "id": 132268092,
        "image": "https://g.foolcdn.com/editorial/images/802417/patient-talking-with-a-physician.jpg",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry.  Both have generally produced strong financial results in 2024, but one wouldn't know it by looking at their stock market performances.  AstraZeneca's shares are down by 2% over the trailing-12-month period, while Novo Nordisk's shares are in the red by 14%.",
        "url": "https://finnhub.io/api/news?id=b757c6c0cc0a5f74b4fbd7fe72329a7d55d99a8c4f2703d4942bb47d234178db"
    },
    {
        "category": "company",
        "datetime": 1735896480,
        "headline": "China\u2019s NMPA prioritises HUTCHMED\u2019s lung cancer therapy review",
        "id": 132249154,
        "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2025/01/Pharma-1-HUTCHMED-shutterstock_2495260393.jpg",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "HUTCHMED is set to gain a milestone payment from AstraZeneca.",
        "url": "https://finnhub.io/api/news?id=964b1eeaba9ebfaf2e6213b9bdbc805d2c7beae9fc07fd872ccff760d1c6c11e"
    },
    {
        "category": "company",
        "datetime": 1735890300,
        "headline": "The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer",
        "id": 132249155,
        "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.",
        "url": "https://finnhub.io/api/news?id=19a8f5d3363fd6f907ef59b816f30cbc03162df4407ca23c13c9dd0cb1d9b032"
    },
    {
        "category": "company",
        "datetime": 1735830120,
        "headline": "MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN",
        "id": 132241488,
        "image": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.",
        "url": "https://finnhub.io/api/news?id=70584a16e63a2e86aa27d4f509eda641935c9956aa6645642652df73c9225364"
    },
    {
        "category": "company",
        "datetime": 1735825260,
        "headline": "5 Large Drug Stocks to Keep An Eye On in the New Year",
        "id": 132242207,
        "image": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.",
        "url": "https://finnhub.io/api/news?id=5c4e85b9cdfce8579155e19b652e5590cfd40b26b8a07a3e0ca3dfb27a46213a"
    },
    {
        "category": "company",
        "datetime": 1735634750,
        "headline": "EWU: The U.K. Is Among The Cheapest Markets In The World",
        "id": 132214008,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/569332611/image_569332611.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "iShares MSCI United Kingdom ETF offers targeted exposure to large- and mid-sized UK companies. Click here to find out why I have a buy rating on EWU.",
        "url": "https://finnhub.io/api/news?id=ecc93cbaf27325211d96a5004ab322dc1475062390fa056051622e8ffee00e5a"
    },
    {
        "category": "company",
        "datetime": 1735576185,
        "headline": "BOE: Losing Its Attraction For Anyone Seeking International Diversification",
        "id": 132206008,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1567445633/image_1567445633.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Investors seeking high yield with equity exposure may consider BlackRock Enhanced Global Dividend Trust, despite sustainability concerns. Click for my BOE update.",
        "url": "https://finnhub.io/api/news?id=bea2d4f28cb93b47c0482405b7fb312312412ed40f7888fe242f5b5295d1fcfe"
    },
    {
        "category": "company",
        "datetime": 1735571242,
        "headline": "Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts",
        "id": 132205036,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178901475/image_2178901475.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Black Diamond Therapeutics shows promise with BDTX-1535 for NSCLC treatment. Click here to find out why I rate BDTX stock a Buy.",
        "url": "https://finnhub.io/api/news?id=1b4d2a740a7dacdc645d543d016e6c7fe991acbdeb34c92f7445cdca7adf2df0"
    },
    {
        "category": "company",
        "datetime": 1735555478,
        "headline": "Is AstraZeneca PLC (AZN) Among the U.K. Dividend Champions for 2024?",
        "id": 132202895,
        "image": "https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the U.K. Dividend Champions List: 2024 Rankings by Yield. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other U.K. dividend champions. In recent years, investors have shown a preference for global stocks, particularly high-growth options like US technology companies, over [\u2026]",
        "url": "https://finnhub.io/api/news?id=84de60266b3c48ea7ab86bb52fefa30e3270a52991ea1fa0e2ab24bf3ace4971"
    },
    {
        "category": "company",
        "datetime": 1735463696,
        "headline": "Is AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?",
        "id": 132195116,
        "image": "https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the U.K. Dividend Aristocrats List: 2024 Rankings by Yield. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other U.K. dividend aristocrats. In recent years, investors have turned away from UK equities, opting instead for global stocks, particularly high-growth options like [\u2026]",
        "url": "https://finnhub.io/api/news?id=efaf8555725bf5783460828e5648bfeb7f9ecb98cbc66f6251394cdf96d3dd5c"
    },
    {
        "category": "company",
        "datetime": 1735341321,
        "headline": "Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know",
        "id": 132182600,
        "image": "https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The latest trading day saw Astrazeneca (AZN) settling at $66.26, representing a -0.39% change from its previous close.",
        "url": "https://finnhub.io/api/news?id=4008a8eb3854baeb7d22472b5bc855b42120028d5f50bc83f3731f667a9ab0d0"
    },
    {
        "category": "company",
        "datetime": 1735310411,
        "headline": "Here's Why Astrazeneca (AZN) is a Strong Value Stock",
        "id": 132175494,
        "image": "https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
        "url": "https://finnhub.io/api/news?id=2522c8f05847f2cf516a05587938cb45e4c22c48e48094d022935b440cbaf195"
    },
    {
        "category": "company",
        "datetime": 1735226340,
        "headline": "AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC",
        "id": 132165499,
        "image": "https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca and Daiichi Sankyo voluntarily withdraw regulatory filing for Dato-DXd in nonsquamous non-small cell lung cancer in the European Union.",
        "url": "https://finnhub.io/api/news?id=ff8ca95c9e03cfeeed4b109ad0c05bfc7ca123584979e7d8fa89da711d015eda"
    },
    {
        "category": "company",
        "datetime": 1735213211,
        "headline": "AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment",
        "id": 132298052,
        "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_2476637021-1.jpg",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The application for Dato-DXd was supported by results from the Phase III TROPION-Lung01 clinical trial.",
        "url": "https://finnhub.io/api/news?id=69641451b9a33ded8c96138136413011d0bfc5e781158a05e2c835e86268bdf7"
    },
    {
        "category": "company",
        "datetime": 1735199509,
        "headline": "Kairos Pharma: Potential To Remove Resistance With Established Drugs",
        "id": 132163701,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962383/image_1386962383.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Kairos Pharma's ENV-105 aims to overcome resistance in CRPC and EGFR-mutant NSCLC, with key data releases expected in 2025. Explore more details here.",
        "url": "https://finnhub.io/api/news?id=13dd7bdadce638afc2bf7f47929662c415e77bfac121dca7c36221645b5869fb"
    },
    {
        "category": "company",
        "datetime": 1735193622,
        "headline": "AstraZeneca's (LON:AZN) investors will be pleased with their respectable 55% return over the last five years",
        "id": 132161957,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/bba95900ab96866c17a285be850152bf",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca PLC ( LON:AZN ) shareholders might be concerned after seeing the share price drop 11% in the last quarter...",
        "url": "https://finnhub.io/api/news?id=7817308785846cbb6d16987052897e364d16f08a387d8b31cf1ab860e51a98fc"
    },
    {
        "category": "company",
        "datetime": 1735137311,
        "headline": "Achilles Therapeutics sells technology assets to AstraZeneca for $12M",
        "id": 132160407,
        "image": "https://media.zenfs.com/en/tipranks_452/bbad1dd12cc6ba90ddd83aeee03f1aae",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Achilles Therapeutics (ACHL) announced that it has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Cancer study to AstraZeneca (AZN). TRACERx, led by Professor Charles Swanton at University College London, UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. As part of the transaction, AstraZeneca will also take over",
        "url": "https://finnhub.io/api/news?id=8eed4552313a7551c9eaa8a2454a38d27c92509a98ea04748adc743153332ebf"
    },
    {
        "category": "company",
        "datetime": 1735121408,
        "headline": "AstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EU",
        "id": 132143810,
        "image": "https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) have voluntarily withdrawn the marketing authorization application in the EU for datopotamab deruxtecan for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer based on the TROPION-Lung01 Phase 3 trial, the companies announced. \u201cThe decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency. AstraZeneca and Daiichi",
        "url": "https://finnhub.io/api/news?id=4be1061345284221bdf55f8ef4c05e0c8465ab023aaafebf612b74481f606e55"
    },
    {
        "category": "company",
        "datetime": 1735034940,
        "headline": "Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million",
        "id": 132625705,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million",
        "url": "https://finnhub.io/api/news?id=23d40301a6349668ca3bf920b686a8d72ac0b1b5acfb2f4fd0652a40dde41414"
    },
    {
        "category": "company",
        "datetime": 1735032571,
        "headline": "AstraZeneca\u2019s Tagrisso gains EC approval for NSCLC treatment",
        "id": 132129137,
        "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/Pharma-1-Astrazeneca-Tagrisso-AZ-UK-DISC-front-3_1.jpg",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The approval was based on the outcomes from the Phase III LAURA trial.",
        "url": "https://finnhub.io/api/news?id=8120bd7518533f5c90c72b6fbd5cc4e2803a6bf6e5647b5699a5d8adcb44c26b"
    },
    {
        "category": "company",
        "datetime": 1735006920,
        "headline": "AstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EU",
        "id": 132625706,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EU",
        "url": "https://finnhub.io/api/news?id=29c3c899652aa1136bc097c2ac97e758f12f392ec3066429f3e2e2a61de58490"
    },
    {
        "category": "company",
        "datetime": 1734978083,
        "headline": "Why Is AstraZeneca PLC (AZN) Among the Best European Dividend Stocks To Buy Now?",
        "id": 132121786,
        "image": "https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 10 Best European Dividend Stocks To Buy. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other European dividend stocks. Dividend payouts for MSCI Europe companies hit a record \u20ac407 billion in 2023, and they are set to grow even [\u2026]",
        "url": "https://finnhub.io/api/news?id=adc69cf73fc390205f10c1c7a2bacf4cdd9b7572a81d6e92f0f385b33aa7f22c"
    },
    {
        "category": "company",
        "datetime": 1734969360,
        "headline": "AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC",
        "id": 132121787,
        "image": "https://media.zenfs.com/en/zacks.com/06708d71c63051ca48bf1855727f077b",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca wins approval in the EU for the label expansion of Tagrisso to treat adult patients with locally advanced, unresectable NSCLC.",
        "url": "https://finnhub.io/api/news?id=0ec210e11b1a49d8844c45ccabc7cbc801efa6729714fe2aa6294da9a983c1df"
    },
    {
        "category": "company",
        "datetime": 1734963820,
        "headline": "Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways",
        "id": 132122209,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166352596/image_2166352596.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Learn about the promising Monopar Therapeutics Inc. MNPR-101 treatment targeting solid tumors and how it aims to reduce investor risk. Click for more on NMPR.",
        "url": "https://finnhub.io/api/news?id=36bc41a3944ccdc35f83be038b4d5b405c1479bc0e3e2f348b2e1b7d3e2e438a"
    },
    {
        "category": "company",
        "datetime": 1734958436,
        "headline": "Jazz Pharmaceuticals: Should Sing A Better Tune In 2025",
        "id": 132121317,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Discover how Jazz Pharmaceuticals' stock is performing post-3Q24 report and FDA approval, highlighting growth in oncology and challenges in neuroscience.",
        "url": "https://finnhub.io/api/news?id=d0da5982633830cff6c0b1eb3afa43b56575a972abb3c78fb0202072a202c3a0"
    },
    {
        "category": "company",
        "datetime": 1734943080,
        "headline": "Hartford International Equity Fund Q3 2024 Commentary",
        "id": 132118476,
        "image": "",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=1892c9e5c02c3cb1da6c44630f59816350abfd030d4a99bbe1897b4e8f6d7b15"
    },
    {
        "category": "company",
        "datetime": 1734930900,
        "headline": "Hartford Healthcare Fund Q3 2024 Commentary",
        "id": 132116815,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
        "url": "https://finnhub.io/api/news?id=437ec63326aa68c908ac079db97d70f4234eaaad235650d5fe23a7620a6c7827"
    },
    {
        "category": "company",
        "datetime": 1734874320,
        "headline": "Hartford International Opportunities Fund Q3 2024 Commentary",
        "id": 132111183,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1463342456/image_1463342456.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Hartford International Opportunities Fund (I Share) underperformed the MSCI ACWI ex- USA Index during the quarter. Read more here.",
        "url": "https://finnhub.io/api/news?id=ed923b30d1193b91d4b3dabd0cea03a32ce140a4abf658f174c2fbbf63f88911"
    },
    {
        "category": "company",
        "datetime": 1734864300,
        "headline": "Is AstraZeneca Stock a Buy?",
        "id": 132108631,
        "image": "https://g.foolcdn.com/editorial/images/801624/physician-giving-medicine-to-elderly-patient.jpg",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way.  Its operations in China were recently rocked when Leon Wang, the company's president in the country -- as well as several other top executives -- were arrested following fraud-related investigations by the authorities.  AstraZeneca expects a sales hit in China, one of its most important international markets.",
        "url": "https://finnhub.io/api/news?id=0e37adc26a7a90115f2d0f1f4e40a9555b42382f0ab4067bd266f376dcb0c482"
    },
    {
        "category": "company",
        "datetime": 1734846531,
        "headline": "4 Ideal Buys From 15 'Safer' Dividends On Bloomberg's 50 December 2025 Watchlist",
        "id": 132108062,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1069616550/image_1069616550.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Bloomberg Intelligence analysts identified 50 watchable companies for 2025. Check out the top dividend-paying companies to watch for in 2025.",
        "url": "https://finnhub.io/api/news?id=9eea8bfc694b2bf9e145320e2b4d6a0287ed6559856f0273c74adea97602847e"
    },
    {
        "category": "company",
        "datetime": 1734736510,
        "headline": "Why Astrazeneca (AZN) Outpaced the Stock Market Today",
        "id": 132088812,
        "image": "https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Astrazeneca (AZN) closed at $65.35 in the latest trading session, marking a +1.41% move from the prior day.",
        "url": "https://finnhub.io/api/news?id=08c094bb3400305a21ff5724484c43935f9b3a8b77c38c17f52fb709e39938d1"
    },
    {
        "category": "company",
        "datetime": 1734705911,
        "headline": "Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick",
        "id": 132075479,
        "image": "https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
        "url": "https://finnhub.io/api/news?id=e3ff05d02c9b7a2cb42dd5b2d7f65d01a49515d897b18b202c0c855e1d6315b6"
    },
    {
        "category": "company",
        "datetime": 1734683572,
        "headline": "Best paying FTSE 100 stocks of 2024",
        "id": 132068977,
        "image": "https://s.yimg.com/ny/api/res/1.2/vcuwDsK3jg4o41CWYa6pFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/fdd0fde0-bde4-11ef-9e97-c4469e2ae967",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "London-listed firms that have served investors well delivering high yields.",
        "url": "https://finnhub.io/api/news?id=384cb73f1ad05814d54341ea974dab4628bf49a9edb67b12f9bb7dd59f4a4e9f"
    },
    {
        "category": "company",
        "datetime": 1734534000,
        "headline": "Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance",
        "id": 132041330,
        "image": "https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The FDA accepts MRK's BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the agency is due on June 10, 2025.",
        "url": "https://finnhub.io/api/news?id=70729b4bebfc89b4bc57769762dae1153fe75f01e41c1ab4eaac64a3d88f4fa0"
    },
    {
        "category": "company",
        "datetime": 1734530700,
        "headline": "Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)",
        "id": 132041331,
        "image": "https://media.zenfs.com/en/cnwgroup.com/9b1b2d84a51eb909d90348d49482f7cf",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo for the treatment of paediatric patients aged two years and above with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). With the agreement in place with the pCPA, individual provinces and territories may now initiate the process to list Koselugo on their formularies, the timing of wh",
        "url": "https://finnhub.io/api/news?id=6c25456a2a4afd7905ed994af50f11bb3947d6ce64468a5227e6ccec7ee27565"
    },
    {
        "category": "company",
        "datetime": 1734526461,
        "headline": "Market Chatter: AstraZeneca's Sales in China Hit by Arrest of Country Head, Oncology Products Affected",
        "id": 132041332,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca's (AZN) sales in China have been hurt following the arrest of its country president, Leo",
        "url": "https://finnhub.io/api/news?id=f65c71c96fe6ece97af06c9c0bafdbdc32713f7319b2f0533e21dcde549a8734"
    },
    {
        "category": "company",
        "datetime": 1734434760,
        "headline": "Hartford International Growth Fund Q3 2024 Commentary",
        "id": 132026210,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/93100504/image_93100504.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "The Hartford International Growth Fund (I share) underperformed the MSCI ACWI ex USA Growth Index during the quarter. Read more here.",
        "url": "https://finnhub.io/api/news?id=2a80cb7f1349b53b642dd2a92f11b7c6bb6bd101ef9a0a348ff488eafeffa0cf"
    },
    {
        "category": "company",
        "datetime": 1734432641,
        "headline": "Is AstraZeneca PLC (AZN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?",
        "id": 132023279,
        "image": "https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at some [\u2026]",
        "url": "https://finnhub.io/api/news?id=82f43ec686d19d05235f39bed2c91c6e568ba489c205c863d62cb3750b69d002"
    },
    {
        "category": "company",
        "datetime": 1734413077,
        "headline": "Merck: Buy Opportunity Backed By Growth",
        "id": 132022536,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate MRK stock a strong buy.",
        "url": "https://finnhub.io/api/news?id=8a5135ec862d828d1354b0aa76a5706e4424ec585dc58bf1464648beee7bae8a"
    },
    {
        "category": "company",
        "datetime": 1734354195,
        "headline": "Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation",
        "id": 132013625,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2174475332/image_2174475332.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Upstream Bio is leveraging TSLP targeting for respiratory disorders treatment, with IPO funds and upcoming Chronic Rhinosinusitis data. Click for more on UPB.",
        "url": "https://finnhub.io/api/news?id=be95c85788fca2450cc3208167c85d94bd0cdf5d53e8e875c80da72bf4ac7b5e"
    },
    {
        "category": "company",
        "datetime": 1734325800,
        "headline": "American Century International Growth Fund Q3 2024 Commentary",
        "id": 132009170,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1402430796/image_1402430796.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Equity markets faced periods of volatility but remained strong to finish the quarter higher. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=81f292d6a298e15cfe3450f5764d394d56553e98917d875800397d4ffda21244"
    },
    {
        "category": "company",
        "datetime": 1734318863,
        "headline": "Altimmune 2025: Redefining Obesity And MASH Treatment",
        "id": 132008513,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132436/image_1359132436.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ALT stock a Buy now.",
        "url": "https://finnhub.io/api/news?id=ed55edde371bee8c7944e37ff4cd9da32bc43eb73ae413bbe17d330bbcac6d71"
    },
    {
        "category": "company",
        "datetime": 1734271200,
        "headline": "Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks",
        "id": 132003797,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/847891380/image_847891380.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Jonathan Faison runs the\u00c2\u00a0ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.",
        "url": "https://finnhub.io/api/news?id=12cbc8633b4aae7f7eb2aff96063c0b26d7980f1aef2937b22b39126b24479b4"
    },
    {
        "category": "company",
        "datetime": 1734260820,
        "headline": "3 Unstoppable Stocks to Buy Right Now",
        "id": 131999003,
        "image": "https://g.foolcdn.com/editorial/images/800812/smiling-person-with-cup-looking-at-laptop.jpg",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Here's why they think AstraZeneca (NASDAQ: AZN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable healthcare stocks to buy right now.  David Jagielski (AstraZeneca): If you're buying a top growth stock, you often have to pay a hefty premium for it, but that isn't the case with AstraZeneca.  Despite having a wealth of products in its portfolio and a lot of growth ahead, the pharmaceutical giant trades at a fairly modest multiple of 15 times next year's estimated profits (based on analyst estimates).",
        "url": "https://finnhub.io/api/news?id=9518e0b443b7c5b63b9c8b281fdffab8fadc009fc736c4aca33de3b2c8b9ab1e"
    },
    {
        "category": "company",
        "datetime": 1734080400,
        "headline": "American Century Focused International Growth Fund Q3 2024 Commentary",
        "id": 131965936,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171573445/image_171573445.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": " Equity markets faced periods of volatility but remained strong to finish the quarter higher as central banks cut interest rates. Click here to read the full fund letter. ",
        "url": "https://finnhub.io/api/news?id=c626bc38aaa7cc6fa610c0fe5379d6f6fa0abf2c35ea6cfacb58502b6530e570"
    },
    {
        "category": "company",
        "datetime": 1734078000,
        "headline": "American Century Focused Global Growth Fund Q3 2024 Commentary",
        "id": 131965424,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487894859/image_1487894859.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "Stocks rebounded from a brief early August downturn fed by fears the Fed wouldn\u00e2\u0080\u0099t act quickly\nenough to stave off a recession. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=bf92e595a5fb6ce0970e86fec96b513b51bc5402713a63583605afa1bcfd9f90"
    },
    {
        "category": "company",
        "datetime": 1734010740,
        "headline": "Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study",
        "id": 131936528,
        "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as both a combination and monotherapy.",
        "url": "https://finnhub.io/api/news?id=822dfed8e26e47081c10638b23d6b263b25032cf2d73bfb99b650f0529dce82c"
    },
    {
        "category": "company",
        "datetime": 1733944218,
        "headline": "AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients",
        "id": 131924099,
        "image": "https://media.zenfs.com/en/Benzinga/ea26a47393d00466b04b8a525b488c58",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) for people with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer. Also Read: After Lung Cancer Approval, AstraZeneca\u2019s Imfinzi Goes Under",
        "url": "https://finnhub.io/api/news?id=944a9b13d62e177356b7d6b51277bf97cb6aec319997021aefb71136a3a083dd"
    },
    {
        "category": "company",
        "datetime": 1733930100,
        "headline": "LYNPARZA\u00ae (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial",
        "id": 131936532,
        "image": "https://s.yimg.com/ny/api/res/1.2/lDf9B8aLBCpUhmChu_iPbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zOTY-/https://media.zenfs.com/en/business-wire.com/8ec7ccdd0c2fab1da78e61eea7bf33a6",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "WILMINGTON, Del., December 11, 2024--Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc\u2019s, known as MSD outside of the US and Canada, LYNPARZA\u00ae (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) at six years for patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer.",
        "url": "https://finnhub.io/api/news?id=cb2d6926e43cc526bbd905315ba600136023f30a7faf2724521004a76f31ebdc"
    },
    {
        "category": "company",
        "datetime": 1733850723,
        "headline": "AstraZeneca\u2019s (AZN) Struggles: Cramer\u2019s Disappointment and Challenges in China",
        "id": 131905700,
        "image": "https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "We recently published a list of Jim Cramer\u2019s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other stocks under Jim Cramer\u2019s lightning rounds\u2019 spotlight. Jim Cramer, host of Mad Money, recently discussed the outlook for the stock market following [\u2026]",
        "url": "https://finnhub.io/api/news?id=90d433717351f2a1a6a18e3dd9a8203c0cef017a3aaee85cea9405e6019e3676"
    },
    {
        "category": "company",
        "datetime": 1733841840,
        "headline": "AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC",
        "id": 131903180,
        "image": "https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "The FDA bestows a Breakthrough Therapy designation to AstraZeneca and Daiichi Sankyo's Dato-DXd for previously treated advanced EGFR-mutated NSCLC.",
        "url": "https://finnhub.io/api/news?id=6c8124ce8920e9326abd00b265431332fde4b7c70d88b7462d3d053056065f31"
    },
    {
        "category": "company",
        "datetime": 1733841611,
        "headline": "Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term",
        "id": 131905702,
        "image": "https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a",
        "related": "AZN",
        "source": "Yahoo",
        "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
        "url": "https://finnhub.io/api/news?id=4b9ef5e7abb02e865d95278fa8a2362a4dcdbd72d31ec36766af7b2be5d72e5a"
    },
    {
        "category": "company",
        "datetime": 1733774114,
        "headline": "Tracking George Soros's 13F Portfolio - Q3 2024 Update",
        "id": 131890146,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451506045/image_1451506045.jpg?io=getty-c-w1536",
        "related": "AZN",
        "source": "SeekingAlpha",
        "summary": "George Soros' 13F portfolio value rose from $5.57B to $6.92B in Q3 2024, with 177 positions. Learn more about the trades and holdings in Q3.",
        "url": "https://finnhub.io/api/news?id=23ba27c3f06964d870b41060251ca435b94957b9151d7d0c2a7648b1bb5d85ee"
    },
    {
        "category": "company",
        "datetime": 1733764920,
        "headline": "AstraZeneca PLC ADR outperforms market on strong trading day",
        "id": 131895113,
        "image": "",
        "related": "AZN",
        "source": "MarketWatch",
        "summary": "AstraZeneca PLC ADR outperforms market on strong trading day",
        "url": "https://finnhub.io/api/news?id=18a23bd5d01265fb7026952ea2eb7c2889cd08d80196fab52cbf6d85817aaed9"
    }
]